CA2530171C - Treatment of degenerative retinal disease via electrical stimulation of surface structures - Google Patents
Treatment of degenerative retinal disease via electrical stimulation of surface structures Download PDFInfo
- Publication number
- CA2530171C CA2530171C CA2530171A CA2530171A CA2530171C CA 2530171 C CA2530171 C CA 2530171C CA 2530171 A CA2530171 A CA 2530171A CA 2530171 A CA2530171 A CA 2530171A CA 2530171 C CA2530171 C CA 2530171C
- Authority
- CA
- Canada
- Prior art keywords
- electrode
- eyeball
- surface structure
- contact
- electrical stimulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000638 stimulation Effects 0.000 title claims abstract description 54
- 208000017442 Retinal disease Diseases 0.000 title claims abstract description 9
- 230000003412 degenerative effect Effects 0.000 title claims abstract description 7
- 210000005252 bulbus oculi Anatomy 0.000 claims abstract description 34
- 210000003786 sclera Anatomy 0.000 claims description 20
- 206010025421 Macule Diseases 0.000 claims description 14
- 210000003205 muscle Anatomy 0.000 claims description 13
- 230000001684 chronic effect Effects 0.000 claims description 10
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 210000001508 eye Anatomy 0.000 abstract description 59
- 230000000694 effects Effects 0.000 abstract description 6
- 238000013459 approach Methods 0.000 abstract description 4
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 abstract 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 description 41
- 230000002207 retinal effect Effects 0.000 description 23
- 238000000034 method Methods 0.000 description 20
- 210000000795 conjunctiva Anatomy 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 11
- 230000007850 degeneration Effects 0.000 description 11
- 230000000007 visual effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 210000004087 cornea Anatomy 0.000 description 9
- 230000004382 visual function Effects 0.000 description 9
- 210000000744 eyelid Anatomy 0.000 description 7
- 108091008695 photoreceptors Proteins 0.000 description 7
- 201000007737 Retinal degeneration Diseases 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000004438 eyesight Effects 0.000 description 6
- 238000010420 art technique Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 210000001328 optic nerve Anatomy 0.000 description 5
- 230000002123 temporal effect Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 108090000099 Neurotrophin-4 Proteins 0.000 description 4
- 206010057430 Retinal injury Diseases 0.000 description 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000003161 choroid Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 210000001760 tenon capsule Anatomy 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 102100033857 Neurotrophin-4 Human genes 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 208000027073 Stargardt disease Diseases 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 210000001775 bruch membrane Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000004258 retinal degeneration Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 2
- 241001116389 Aloe Species 0.000 description 1
- 241000796533 Arna Species 0.000 description 1
- 208000033810 Choroidal dystrophy Diseases 0.000 description 1
- 101100130497 Drosophila melanogaster Mical gene Proteins 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 description 1
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 description 1
- 240000007591 Tilia tomentosa Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000000411 amacrine cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000027129 choroid disease Diseases 0.000 description 1
- 208000003571 choroideremia Diseases 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000001323 spiral ganglion Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0543—Retinal electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/326—Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36046—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of the eye
Abstract
To provide indirect electrical stimulation for treatment of degenerative retinal diseases, such stimulation is applied to surface structures of the eye. A source (224) of an electrical stimulation signal is coupled to a first electrode (226) configured for contact with a first internal surface structure of an eyeball. A second electrode (228), which may be configured either for contact with an internal surface structure or an external surface structure of the eyeball, is also coupled to the source. The source of the electrical stimulation signal may be implemented internal to a body of a patient, external to the body or through a combined internal/external approach. The first and second electrodes are preferably arranged such that the circuit created by the source, electrodes and intervening biological tissue provides trans-retinal electrical stimulation to thereby effect treatment.
Description
TREATMENT ~F DEGENERATIVE RETINAL DISEASE VIA ELECTRICAL
STIMULATI~N ~F SURFACE STRUCTURES
FIELD ~F THE INVENTI~N
[0001] The present invention relates to treatment of degenerative retinal disease and, in particular, to methods and apparatus for treatment thereof based on external electrical stimulation.
BACKGROUND
STIMULATI~N ~F SURFACE STRUCTURES
FIELD ~F THE INVENTI~N
[0001] The present invention relates to treatment of degenerative retinal disease and, in particular, to methods and apparatus for treatment thereof based on external electrical stimulation.
BACKGROUND
[0002] Many human retinal diseases cause vision loss by partial to complete destruction of the vascular layers of the eye that include the choroid and choriocapillaris, both of which nourish the outer anatomical retina and a portion of the inner anatomical retina of the eye.
[0003] Many other retinal diseases cause vision loss due to partial or to complete degeneration of one or both of the two gnatomical retinal layers directly, due to inherent abnormalities of these layers. The components of the retinal layers include Bruch's membrane and retinal pigment epithelium which comprise the "outer anatomical retinal layer", and the photoreceptor outer and inner segments, outer nuclear, outer plexiform, inner nuclear, inner plexiform, amacrine cell, ganglion cell and nerve fiber layers which comprise the "inner anatomical retinal layer", also known as the "neuroretina". The outer portion of the neuroretina is comprised of the photoreceptor outer and inner segments and outer r?~aclear layer ~c~ll f~oraie~; ~f the ph~atoreceptors~ and is als~
Known as the "outer retina" which is to be distinguished iron ~ the "outer gnat~mical retinal layer" as defined above. Loss of function of the outer retina is c~mmeanly the result cal dysf~ancti~n of the outer gnat~r~rrical retina) layer that provides nourishment to the outer retina and/or to direct defects of the outer retina itself. The final common result, however, is dysfunction of the outer retina that contains the light sensing cells, the photoreceptors. Some of these "outer retina" diseases include age-related macular degeneration, retinitis pigmentosa, choroidal disease, long-term retinal detachment, diabetic retinopathies, Stargardt's disease, choroideremia, best's disease, and rupture of the choroid. The inner portion of the neuroretina, however, often remains functionally and anatomically quite intact and may be activated by the appropriate stimuli.
Known as the "outer retina" which is to be distinguished iron ~ the "outer gnat~mical retinal layer" as defined above. Loss of function of the outer retina is c~mmeanly the result cal dysf~ancti~n of the outer gnat~r~rrical retina) layer that provides nourishment to the outer retina and/or to direct defects of the outer retina itself. The final common result, however, is dysfunction of the outer retina that contains the light sensing cells, the photoreceptors. Some of these "outer retina" diseases include age-related macular degeneration, retinitis pigmentosa, choroidal disease, long-term retinal detachment, diabetic retinopathies, Stargardt's disease, choroideremia, best's disease, and rupture of the choroid. The inner portion of the neuroretina, however, often remains functionally and anatomically quite intact and may be activated by the appropriate stimuli.
(0004] While researchers have reported efforts to restore visual function in humans by transplanting a variety of retinal cells and retinal layers from donors to the subretinal space of recipients, no sustained visual improvement in such recipients has been widely accepted by the medical community.
(0005] Multiple methods and devices to produce prosthetic artificial vision based on patterned electrical stimulation of the neuroretina in contact with, or in close proximity to, the source of electrical stimulation are known.
These devices typically employ arrays of stimulating electrodes powered by photodiodes or microphotodiodes disposed on the epiretinal side (the surface of the retina facing the vitreous cavity) or the subretinal side (the underneath side) of the neuroretina. For example, Chow et al. have described various designs for implants to be inserted in the sub-retinal space, i.e., a space created between the inner and outer retinal layers, in U.S. Patent I'los.
5,016,633; 5,024,223; 5,397,350; 5,556,423; 5,895,415; 6,230,057; 6,389,317 and 6,427,087. Generally, the implants described in fihese patents are placed in contact with the photoreceptor layer of the inner retina such that electrodes on the implants can provide stimulating currents, derived from the photovoltaic conversion ~f incident light, to the inner retina. additionally, technia;ues and devices f~r inserting such irnlalants int~ the scab-re~:ii~~l s~a~~e are ~Isc~
described in various ones ~f these patents, e.g., U.~. Pat. i~os. 5,016,633;
5,~2~4,~~3 and 6,389,3'i7.
(!~0~~] Cellular electrical signals also play important developmental roles, enabling nerve cells to develop and function properly. For example, nerve cells undergo constant remodeling, or "arborization", during development related to electric signaling. First an extensive preliminary network is formed that is then "pruned" and refined by mechanisms that include cell death, selective growth, loss of neurites (axonal and dendritic outgrowths), and the stabilization and elimination of synapses (Neely and Nicholls, 1995). If a neuron fails to exhibit or is inhibited from transducing normal electrical activity during arborization, axons fail to retract branches that had grown to inappropriate positions.
[0007] The application of electric currents to organ systems other than the eye is known to promote and maintain certain cellular functions, including bone growth, spinal cord growth and cochlear spiral ganglion cell preservation (Acheson et al., 1991; Dooley et al., 1978; Evans et al., 2001; Kane, 1988;
Koyama et al., 1997; Lagey et al., 1986; Leake et al., 1991; Leake et al., 1999; Politis and ~anakis, 1988a; Politis and Zanakis, 1988b; Politis and Zanakis, 1989; Politic et al., 1988a; Politis et al., 1988b).
[0008] In other studies, the application of growth and neurotrophic-type factors was found to promote and maintain certain retinal cellular functions.
For example, brain-derived neurotrophic factor (BDNF), neurotrophin-4. (NT-4), neurotrophin-5 (NT-5), fibroblastic growth factor (F~F) and glial cell line-derived neurotrophic factor (C~DNF) have been shown to enhanced neurite outgrowfih of retinal ganglion cells and to increase their survival in cell culture.
GDNF has been shown to preserve rod photoreceptors in the rd/rd mouse, an animal model of retinal degeneration. Nerve growth factor (NGF) injected into the intra-ocular area of the D3H mouse, also a model of retinal degeneration, results in a significant increase of surviving photoreceptor cells compared to controls (Eosco and Linden, 1999; Caleo et al., 1999; Carmignoto et al., 1989;
~'ui et al., 1998; Frasson et al., 1999; Lambiase and Aloe, 1990; I~eh et al., 1990). i~J~e~ methods or devices, I~owever, t~2 imlarc~~e'dhe gei-~er~~l inherent visual function of damaged retinal cells distant front a s~urce ~f electrical stim~alati~n through tl-~e use of cl-~r~nic electrical stimulation a~a~alied t~ t1 ~e neuroretina from either within tile eye ~r indirectly via contact with surface structures of the eye are known.
i3RIEF SUMMARY
[0009] The present invention provides techniques for preventive or therapeutic treatment of degenerative retinal disease through the application of electrical stimulation. In particular, the present invention concerns the use of electrical stimulation applied to surface structures of an eyeball for such treatment. Generally, this is achieved with a device comprising a source of an electrical stimulation signal coupled to a first electrode configured for contact with a first internal surface structure of an eyeball and a second electrode configured for contact with a second surface structure of the eyeball, which second surface structure may be external or internal. Surface structures of the eyeball may be categorized as either external surface structures (e.g., conjunctiva and cornea) or internal surface structures (e.g., sclera, episclera, intramuscular septum, Tenon's capsule, extraocular muscles or tendon, etc.).
The source of the electrical stimulation signal may be implemented internal to a body of a patient, external to the body or through a combined internal/external approach. Electrodes in accordance with various embodiments of the present invention may be arranged in one or more ring formations, including interleaved electrodes. The electrodes are preferably arranged such that a circuit created by the source, electrodes and intervening biological tissue provides traps-retinal electrical stimulation to thereby effect treatment.
SRIEF ~ESCRIPTI~~I ~F THE ~RAI~Ih~GS
E9~~ 0] FIG. ~ is a cross-sectional top view of a human eye.
[Q;~~~] FIG. ~ is a cr~ss-section thrczugh a htai~an eye indicating layers of the outer anal inner anatomical retina, as indicated by the inset of FIG.
'l.
[0~~ ~] FIG. ~ is a schematic bl~ch diagram ~f a prior art technique f~r indirect electrical stimulation.
[003] F1G. 4. is a schematic block diagram of another prior art technique for indirect electrical stimulation.
(0014] FIG. 5 is a schematic block diagram of yet another prior art technique for indirect electrical stimulation.
[0015] FIG. 6 is a schematic block diagram of a technique for indirect electrical stimulation in accordance with the present invention.
[0016] FIG. 7 is a schematic block diagram of another technique for indirect electrical stimulation in accordance with the present invention.
[0017] FIG. 8 is a partial cross-sectional side view of a human eye and surrounding structures.
[0018] FIG. 9 is a partial cross-sectional magnified view of a region of the eye illustrated in FIG. 8.
(0019] FIG. 10 is a side view of a human eye illustrafiing application of a corneal electrode in accordance with an embodiment of the present invention.
(0020] FIG. 11 is a side view of a human eye illustrating application of an epi-conjunctival electrode in accordance with an embodiment of the present invention.
[0021] FIG. 12 is a side view of a human eye illustrating application of a fiber electrode in a conjunctival fornix in accordance with an embodiment of the present invention.
[0022] FIG. 13 is a side view of a human eye illustrating application of a plurality of electrode arrays applied to an internal surface structure in accordance with an embodiment of the present invention.
[OO~~j FIG. °I~ is u~ ~id~ vie~,~ of a h~arna~~ e~~ illustrd~ii~~
appli~atioi~ on an electr~c~e array to an internal surface structure ire accorolance with an embodiment of the present inventi~n.
(~~2a~] Flt. 15 is a schematic block dia~qram of an internal surface structure/internal surface structure technique for indirect electrical stimulation in accordance with the present invention.
(0025] FIG. 16 is a schematic block diagram of an internal surface structure/exfiernal surface structure technique for indirect electrical stimulation in accordance with the present invention.
(0026] FIG. 17 is a top view of a human eye illustrating an exemplary implementation of the embodiment of FIG. 15.
(0027] FIG. 10 is a top view of a human eye illustrating a first exemplary implementation of the embodiment of FIG. 16.
(0025] FIG. 19 is a top view of a human eye illustrating a second exemplary implementation of the embodiment of FiG. 16.
DETAILED DESCRIPTI~N ~F THE
PRESENTLY PREFERRED EME~DIMENTS
(0029] In the course of testing for the safety and efficacy of retinal implants in humans blinded by retinitis pigmentosa, an unexpected and surprising observation was made: even though the implants were pieced at a discrete location in the subretinal space (acting as a prosthesis), vision was improved not only in those discrete locations as ea~pected, but also in distant locations of the retina. Thus chronic electrical stimulation in specific locations enhanced retinal cell function throughout the eye. This "halo effect" can be used to improve vision in those individuals who suffer from diseases, conditions and traumas that have damaged the outer retinal layer but leave the inner retinal layer at least partially intact. Although prosthetic electrical devices designed to replace damaged or missing retinal cells have been used to treat vision l~a~s caused I~a~r ~a~ater rel:inal degeneration, electrical ~,tirr~~alation t~ im~ar~ve large areas ~f retinal cell visual function is novel. s~s a non-Ilrr~ltinc~
ea~planation, the promoti~n of irnpr~ved retinal cell visual functi~n by chronic electrical stirnuiati~n rnGiy be e~zplained by the stin~~alation of pr~ad~acti~n and release of growth factors; more specifically, neurotrophic-type growth factors, by the stimulated retinas. The synthesis andlor secretion of neurotrophic factors would then improve retinal cell function and survival in conditions where these activities would be lost.
_5_ [0030] Accordingly, the present invention discloses both novel devices and methods to electrically stimulate the retina to improve large areas of retinal visual function and to protect the retina from degeneration. As described in greater detail below, the devices and methods disclosed herein may be generally categorized as indirect. Direct techniques involve stimulation of a retina wherein the stimulus traverses substantially no intervening biological structures. Conversely, indirect techniques encompass stimulation of a retina wherein the stimulus must traverse one or more intervening biological structures.
SubjectlPatient [0031] A subject (patient) may be a human being or a non-human animal, but is preferably a human. Usually the individual has suffered some type of retinal damage and/or degeneration that results in some degree of visual loss and/or has a condition that will result in retinal damage and/or degeneration. A normal (healthy) subject does not have a condition that will result in retinal damage and/or degeneration and/or has not suffered retinal damage and/or degeneration.
Irnpr~~ing visual fun~ti~~
[0032] Improving visual function refers to improving a targeted function of the eye, selected by the artisan, and includes improving any to all of the following capabilities of the eye, retina and visual system: perception of brightness in the presence of light, perception of darkness in the absence of li~~,hx, perc~laiions of con trust, oolor, sh~~p~ 7 res~al~ationY rnoa~emen t and visual field size.
[~~~3] Primary visual degradation means loss of ~eisua! functi~n due to malfuncti~ning, damaged ~r degenerati~n of structures found in tile eye.
Secondary visual degradation means loss of visual function glue t~ secondary damage, typically from lack of use of the vision-associated portions of the brain. Improving visual function means to improve the visual function of primary visual degradation, secondary visual degradation or both.
Eye%yeball [0034] The eye (or eyeball) has the usual definition in the art. Eye includes all interior and exterior surfaces, components, contents and cavities of the eye. The eye does not include the eyelid or optic nerve.
[0035] The retina of the eye can be divided into sectors as is commonly accepted in the art. Such sectors are described by the use of the terms temporal, nasal, superior, inferior, by clock hour designation, and by the number of degrees away from the macula. For example, the temporal sector of the retina is the retina temporal to a perpendicular plane cutting through retina from the 12 o'clock to the 6 o'clock positions and through the macula.
In another example, the superior sector is the retina superior to a perpendicular plane cutting through the 9 o'clock to 3 o'clock positions and through the macula. In a further example, the superior-temporal sector is the intersection of these two sectors, a pie-shaped area delineated from the 9 o'clock position of the peripheral retina to the macula and then clockwise to the 12 o'clock position. I~lore specific locations of the retina can be designated by degrees away from the macula and clock hour location: for example, ~0 degrees away from the macula at the 3 o'clock (nasal) position.
The number of degrees away from the macula is in visual axes degrees.
These axes all intersect through the lens of the eye.
(0036] The visual field sectors correspond oppositely to the retinal secfiors as is commonly understood in the art. For example, the superior-temporal sector of the retina corresponds to the inferior-nasal portion of the vis~a~l field.
Pe~i~~re6 ~1 [~0~~~] T~ lae ~aeripher~~l to an ob)ect, device ~r ~ther lanc~marl~ in eludes all surroun~9inc~ parts, but not the object, device or la~ldmarl~, i. e., the object, device or landmark, together with the peripheral portion, constitutes the whole.
Light (003] Light refers not only to the electromagnetic spectrum that humans can readily perceive visually (approximately 400 nm to 750 nm), but also includes ultraviolet light (<400 nm in wavelength) as well as infrared light (>750 nm in wavelength).
Indications (0039] The invention can be used to improve visual function in subjects in which the retina is damaged by disease, degeneration, condition, or trauma and/or to slow down or stop the progression of damage by disease, degeneration, condition or trauma. Common diseases, conditions, degeneration or trauma that are particularly amenable to this treatment include age-related macula degeneration, retinitis pigmentosa, Leber's congenital amaurosis, Stargardt's disease, best's disease, diabetic retinopathy, long-term retinal detachment, and choroidal damage.
~~e str~caetu~-~
(~04~] Deferring to the drawings, FIG. 1 illustrates a section through the eyeball. The neuroretina 150 comprises multiple layers of cells and structures (see FIG. 2). The photoreceptor components of the retina are situated within the neuroretina which covers the internal posterior cavity of the eye, terminating anteriorly at the ore serrate 167. The ciliary body 165 and the iris 162 are covered by extensions of the retina, lacking photoreceptor components. The outermost layers of the eye consist of the sclera 164 and corr~~~ ~ 155. The -c~(er~~ i~ ~~i~~r~'~~a l~az~ ~:h~~ eiiir~rgin~~ optics ne~~~e °i~a5. The: left 150 and vitreous cavity 154 are als~ indicated. The macula 15g of the retina is typically a ~ inm by 5 mm oval f-ec~i~t1, at the center of whicll is the fovea 170.
(~0~~~] The layers of the eye at the posterior p~le from inside to outside are shown in FIG. 2: internal limiting membrane 40, nerve fiber layer 42, ganglion cell layer 44, inner plexiform 46, inner nuclear layer 45, outer plexiform 50, outer nuclear cell layer 52, and photoreceptor outer and inner _g_ segment layer 54, all of which constitute the anatomical inner retinal layer, also known as the neuroretina 56. The retinal pigment epithelium 58 and Bruch's membrane 60 constitute the outer retinal layer 62. The choriocapiliaris 64 and choroid 66 comprise the choroidal vasculature 68. The outer coat of the eye is the sclera 70. Light 156 enters the retina as shown.
Indirect Stimulation [0042] In prior applications, I have disclosed embodiments possessing a common characteristic fihat the electrical stimulus is provided directly to the neuroretina, i.e., there are substantially no intervening biological structures.
In accordance with the present invention, electrical stimulus may be applied to the neuroretina in an indirecfi fashion, i.e., via one or more intervening biological structures.
[0043] Various methods for indirect stimulation, as that term is defined herein, are known. FIGS. 3-5 are schematic illustrations of such prior art techniques. FIG. 3 illustrates a technique (described in U.S. Patent No.
5,14.7,28q~ issued to Fedorov et al.; hereinafter "Fedorov") in which electrical stimulation is applied to an eye 204. of a patient 202 via a pair of surgically implanted electrodes 210, 212 applied to surfaces of the eye 204 and optic nerve 206. A source of electrical stimulation 208 is provided coupled to the pair of electrodes 210, 212. In practice, the source 208 comprises an induction coil that provides electrical currents as a result of magnetic fields applied to the temporal region of the patient 202. llVhile Fedorov reports improved vision in patients, the circumstances under which the patients were tr~~sue~3 ~r~. lira's I<~n~awf-~ ~n~1 ~3~a nc~~ ~~ape~r to h~~\A~ E~~~en s~a~~~~~~;,tv~-~ °~Ka p,w~Lr reviev~. i~ioreover, it will be reaelily evident to those having ordinary skill in the art that the implantati~n ~f an electrode in el~se pro~~imity t~ the ~ptic nerve 206 requires highly invasive and complicated surgery.
[0044] FIG. 4 illustrates a more recent technique proposed by Ghow in U.S. Patent No. 6,427,087. In particular, an electrode 210' is placed in contact with tissues of the eye 204, whereas another electrode 212' is placed within the vitreous cavity 205 that may be in confiact with the internal limiting membrane (see also the vitreous cavity 154 illustrated in FIG. 1). It is believed that the resulting traps-retinal stimulation resulting from this configuration will result in more efficient stimulation.
[0045] Yet another approach is illustrated in FIG. 5 in which the stimulating 210" and return 212" electrodes, rather than being in direct contact with the eye 204, are instead placed upon external tissues 214, 216.
Examples of this approach (sometimes referred to as microcurrent stimulation), particularly for the purpose of treating degenerative retinal diseases such as macular degeneration and retinitis pigmentosa, are taught in U.S. Patent No. 5,522,864 to Wallace et al. and U.S. Patent Nos. 6,035,236 and 6,275,735 to Jarding et al. Typically, the stimulating electrode 210" is coupled to external tissue in close proximity to the eye 204, e.g., the eyelid, and the return electrode 212" is coupled to distal external tissues such as the occipital lobe or arm of the patient 202. While anecdotal evidence of efficacy has been sporadically reported, no controlled, peer reviewed studies on humans are Known to have been performed and, furthermore, the American Academy of ~phthalmology's Taslc Force on Complementary Therapies concluded in September 2000 that "strong evidence has not been found to demonstrate the effectiveness of microcurrent stimulation treatment of [age-related macular degeneration] compared to standard therapies."
[0046] In contrast to the prior art techniques described above, the present invention encompasses indirect stimulation techniques based on application of one or more electrodes to surface structures of the eye, as opposed to peripheral structures such as the optic nerve or eyelids. ~s used herein, s~ai~face str~act~ar~os of the eye may be divided irn~ dw~a classes, internal surface structures and eazternal surface struet~ares as described in greater detail below. In general, surface str~act~ares of tile eye may he aiefirred as and of several laminae (taeginning most interi~rly with the sclera in the case ~f internal surface sfiructures) and forming or surrounding the eye, depending upon the specific region of the eye under consideration.
[0047] P, schematic illustration of an embodiment of indirect stimulation in accordance with the present invention is presented in FIG. 6. In this _11_ embodiment, at least one active or stimulating electrode 226 is applied to a surface structure of an eye 220. The at least one active electrode 226 is configured for chronic contact with the surface structure of the eye 220. As used herein, the term chronic encompasses not only continuous periods of time but also repetitive and/or periodic intervals of time. For example, fibs at least one active electrode 226 may be substantially permanently attached or otherwise coupled to the surface structure, or it may be configured to allow for repetitive placement in contact with, and subsequent removal from, the surface structure over a period of time established by a course of treatment.
At least one return or ground electrode 22~ is configured for application to tissues 222 substantially distant from the eyeball 220, e.g., outside the orbit of the eye. For example, in this embodiment, the at least one return electrode 22~ may be coupled to the temporal or occipital skull regions of the patient or, more distally, to the neck, shoulder, chest, arms or legs of the patient.
Additionally, the at least one return electrode 22~ may be configured for chronic or temporary application to the tissue 222. For example, the at least one return electrode 22~ may comprise one or more implantable electrodes substantially permanently coupled to the tissue 222 or it may comprise orle or more temporary cutaneous electrodes secured with an adhesive and electrically coupled using a suitable conductive gel. Positioned in this manner, and given the relatively low resistance of the vitreous relative to the surface structures and surrounding tissues of the eye, the active and ground return electrodes establish a traps-retinal circuit such that application of an electrical stimulation signal t~ the active electrode will result in beneficial traps-retinal c~arrei ~fds.
~~~a~~ In addition to the electr~des 226, 22~, the system illustrated in FI~. 0 also comprises a s~~arce of the electric al stirr~ulation sio~nal. The particular c~nfig~aration of the s~~aree depends on whether the source is implemented entirely internally or externally, or combined internally and externally, relative to the patient. For example, in the case where only the active electrode 226 is configured to removably contact external surface structures of the eye and the return electrode 2213 is configured for temporary _ ~2 _ cutaneous contact, the source may comprise one or more input terminals 224 for application of the electrical stimulation signal to the electrodes. In this case, the electrical stimulation signal is provided by an extraocular signal source 224'.
[0049] Alternatively, the source 224' may be entirely internal to the patient 202' as in the case of an implantable battery and, optionally, signal generation circuitry (not shown). In this case, it is assumed that the at least one return electrode 220 is likewise chronically implanted in the patient 202', thereby vitiating the need for any input terminals 224.
[0050] Further still, the source may be implemented as a combination of internal 224' and external 224" (relative to the patient) components. For example, the internal source component 224' may comprise a receiver induction coil implanted subcutaneously and the external source component 224" may comprise transmitting coil that may be precisely aligned with the receiver induction coil. As known in the art, such transmitter/receiver coil pairs may be used to transmit power and data that may be used to provide the electrical stimulation signal.
[00~~] In practice, the electrical stimulation signal provided by the source may comprise virtually any type of waveform demonstrating a beneficial effect. For example, the electrical stimulation signal may comprise an anodic or cathodic direct current signal or a time-varying waveform such as a square, sine, triangular, saw tooth signal or any other similar waveform.
Preferably, the electrical stimulation signal comprises a bi-phasic waveform that is balanced in the sense a net zero charge is applied to the retina over a perioc9 a~f tune. Ti its may be e~chieved, bar v~eay of n on-e~~ha~as,tive e~aarnteles, through r~l~re use of a signal cornprisine~ a continuous train of equal-duratiorl &ai-phasic pulses; eqr,aal-ol~aration tai-phaeic pulses separater2 by peri~ds of quiescence; varying duration and amplitude bi-phasic, charge balanced pulses; combinations of the above; etc. Pulse frequencies may range anywhere from 10 KH~ down to 0.001 Hz or, in the extreme, even a continuous monophasic waveform, i.e., 0 H~. Those having ordinary skid in the art will appreciate that the particular type of electrical stimulation signal _ 1~ _ used is a matter of design choice and is selected so as to provide maximum beneficial effect.
[0052] A schematic illustration of another embodiment of indirect stimulation in accordance with the present invention is presented in FIG. 7.
In this embodiment, the at least one active electrode 226 is applied to a first surface structure of the eye 220 and the at least one return electrode 228 is applied to a second surface structure of the eye 220. In practice, the first and second surface structures may be the same or different surface structures.
The source 224, 224', 224" of the electrical stimulation signal in this embodiment may comprise any of the alternatives described above relative to FIG. 6. Pt is anticipated that the embodiment of indirect stimulation illustrated in FIG. 7 will provide heightened stimulation of the retina given the relative proximity of electrodes to the retina. The various surface structures applicable to the present invention are further described below with reference to FIGs. 8 and 9.
[~0~3] E~eferring now to FIG. 8, an eye and surrounding structures are illustrated. The ocular orbit is defined by bone structures 230, 231. V~ithin the orbit, a layer of extraconal fat 233 and intraconal fat 235 surround the eyeball.
The fat layers 233, 235 are separated from each other by a cone defined by superior 236, inferior 238 and lateral 240 extraocular muscles as well as an intermuscular septum 242 connecting fibs muscles. The optic nerve 166 exits the orbit posteriorly, whereas the anterior portion of the eyeball is formed by a portion of the sclera and the cornea 158. The so-called Tenon's capsule 24.4 (partially shoevn) separates the eyeball from the orbital fat and forms a socleet witPlin whicPl the eyeball moves. The upper and laar~er eyelids 245, 24 i enclose and protect the anterior portion of the eyeball. The conjunctiva c~mprises the bulbar con junctiva 150' overlying the anterior pcarti~n ~f the sclera and the palpebral conjunctiva 15g" overlying the Pnner surface ~f the upper and lower eyelids 246, 247. The fold between the bulbar and palpebral conjunctiva 159', 159" gives rise to a conjunctival fornix 250. In the context of the present invention, external surface structures comprise those surface structures that are accessible via the palpebral fissure defined by the eyelids, _ 1 Q. _ i.e., the cornea 158 and the conjunctiva 159. Internal surface structures are defined as those surface structures posterior to the bulbar conjunctiva 159' and comprise the various laminae beginning with the sclera and its overlying structures, which overlying structures are dependent upon the particular region of the eyeball under consideration.
[0Q54] FIG. 9 schematically illustrates the various surface structures present at the exemplary region indicated in FIG. 8. The dimensions shown are not to scale. The sclera 164 forms the innermost surface structure.
Moving outwardly from the sclera 164, the episclera 260 is a thin, loose layer of connective tissue forming the outer surtace of the sclera 164. The intermuscular septum 242 resides above the episclera 260, and Tenon's capsule 244 resides above the intermuscular septum 242. Each of the layers illustrated in FIG. 14 comprises, for purposes of the instant invention, a separate surface structure to which an electrode may be applied. Those having ordinary sfcill in the art will appreciate that other regions of the eyeball may have surfiace structure layers different from those illustrated in FIG. 9.
[005~~ carious exemplary implementations of the embodiments of FIGS. 6 and 7 are schematically illustrated with respect to FIGS. 10-14~. For reference, each of FIGs. 10-12 illustrate the superior 236, inferior 238 and lateral 240 extraocular muscles, the upper and lower eyelids 246, 247 and the cornea 158. FIG. 10 illustrates an embodiment in which a contact lens body 265 supports one or more corneal electrodes 266. Various materials for fabricating the supporting body 265 and the at least one corneal electrode 266 are l5nown to those having ordinary shill in the art. ~Ithough it is preferred that the at least one corneal electrode 266 C~ae employed as an active elects or~le, it may likewise be employed as a return electrode. (This is also true of the rather embo~linlents illustrated in FIGS. 11 and 12.j The at least one corn cal elects°ode 266 may comprise a plurality of discrete electrodes arranged, for example, in a ring formation affi~ced in proximity to the periphery of the supporting body 265, or may comprise a single annular electrode similarly affixed to the supporting body 265. Alternatively, the at least one corneal electrode 266 may be arranged closer to the centre! region of the cornea.
_15_ Where a plurality of electrodes 266 are employed, each electrode may be individually selectable, i.e., each of the electrodes is separately addressable and the electrical stimulation signal may be applied to each electrode individually. When the electrical stimulation signal is applied, current will flow through the cornea and vitreous cavity, across the retina and back to the return electrode. Note that, for ease of illustration, none of FIGs. 10-12 illustrate the complementary electrode, nor do FIGs. 10-14 illustrate the electrical connections between the electrodes and the source of the electrical stimulation signal, which connections will be readily devisable as a matter of design choice by those having ordinary skill in the art.
[0056] FIG. 11 illustrates another embodiment in which an annular supporting body 270 provides support for at least one epi-conjunctiva) electrode 271. ~nce again, various materials for fabricating the supporting body 270 and the at least one epi-conjunctiva) electrode 271 are known to those having ordinary skill in the art. As in the embodiment of FIG. 10, the at least one epi-conjunctiva) electrode 271 may comprise a plurality of individually selectable electrodes or a single annular electrode as a matter of design choice. In the example shown in FIG. 11, the at least one epi-conjunctival electrode 271 contacts the bulbar conjunctiva 159' in close proximity to the cornea 158. However, additionally or alternatively, the at least one epi-conjunctiva) electrode 271 may be placed more distally from the cornea 158 and yet still in contact with the bulbar conjunctiva 159'.
Regardless, current flow will traverse the bulbar conjunctiva 159', the sclera, vitreous cavity and retina.
[~9~~7] FIG. °I2 illustrates yet ane~ther emb~dir~lent in which an electrode 275 is placed in epi-conjunctiva) contact v~ithin the conjunctiva) fornix 250.
In practice, the electrode 275 may comprise a fibrous or filamentary electrode such as a "~TL" electrode. ~TL electrodes are particularly advantageous because they are known to be well tolerated by patients given their relatively slender dimensions. Although a single electrode is illustrated in the lower conjunctiva) fornix 250, an electrode may also be placed in the upper conjunctiva) fornix as an alternative, or in addition to, the lower electrode.
_15_ Furthermore, more than one electrode can be placed into either of the fornices at a single time. As in the embodiment of FIG. 11, current flow in the embodiment of FIG. 12 will traverse the bulbar conjunctiva 159', the sclera, vitreous cavity and retina.
[005~J Each of FIGs. 10-12 illustrates embodiments in which electrodes are placed in contact with external surface structures of the eye. FIG. 73 schematically illustrates an embodiment in which electrodes are applied to internal surface structures. In particular, one or more supporting rings 281-283 are implanted in contact with internal surface structures. Note that although the third ring 283 is placed in contact with a substantially anterior portion of the eye, it is implanted beneath the bulbar conjunctiva 159'.
However, a hybrid internaUexternal surface structure technique may be possible if the third ring 283 were placed above the bulbar conjunctiva 159' in a manner similar to that illustrated in FIG. 11. (Such hybrid arrangements are further described with reference to FIGS. 16, 18 and 19 below.) Techniques for introducing such rings into the orbit and for securing them to the eye are know in the art, particularly from the use of so-called scleral buckles. For example, each ring may be sutured in place in accordance with such techniques. Note that the first and second rings 281, 282 are preferably placed beneath the extraocular muscles 236, 238, 240 in accordance with known techniques.
[0059] Each ring comprises at least one electrode 285 and, in a preferred embodiment, each ring comprises a plurality ofi electrodes. Suitable materials for fabricating the supporting rings and electrodes are known to those i~tavitlg ordinary shill in the art. Preferably, each electrode is individually selectable. Additi~tlally, each individual electrode may be electrically c~nfigured to act as an active elecvr~ade ~r a return electrode. In this rnanner, each ring 28'i-283 may comprise both active and return electrodes. Irr such an embodiment, it may be preferable to interleave active and return electrodes and, further, to antipodally arrange the active and return electrodes. An antipodal arrangement of electrodes will give rise to a trans-retina! current path that is substantially perpendicular to the retinal surface.
_17_ Additionally, being individually selectable, each electrode in an antipodal electrode pair could be periodically switched between active and return operation. Further still, electrodes between rings could be activated as stimulating pairs, e.g., an electrode from a first ring 281 could be operated as an active electrode and an electrode from a second ring 282 could be operated as a return electrode, and vice versa. Although a specific number of supporting rings 281-283 positioned in substantially vertical orientations are illustrated in FIG. 13, it is understood that a greater or lesser number of such rings could be employed and, further, that the orientation of such rings need not be limited to substantially vertical. Taken to an extreme, the supporting rings 281-283 could be eliminated and, instead, each electrode 285 may comprise a separate, independent supporting member such that individual electrodes may be implanted at specific locations on specific internal surface structures.
[0060] Yet another embodiment providing contact with internal surface structures is illustrated in FIG. 14. In this embodiment, one or more supporking sheaths 290 comprising a plurality of electrodes 292 are positioned and secured in contact with internal surface structures of the eye. The discussion above with regard to individually selectable and antipodal electrodes relative t~ FIG. 13 equally applies to the arrangement of FIG. 1.4.
To accommodate the presence of various ocular structures, such as the connections between the various muscles 236, 238, 2~0 and the sclera, openings 294 may be provided. In the example illustrated in FIG. 14, a plurality of sheaths 290 are provided such that each sheath 290 covers the surfaces between ac9)acent muscles wi°dl ~ the ~pei ~ii~gs 29~ thereby being formed by the ad)acency of the sheaths 290 when implanted. In the case where a ~,ingle sheath 290 surrounds at least one of the muscles, the ar~tm-i~r portion o~~ the rapening 29q~ could be fabricated such that a unitary body is provided (illustrated with dotted lines) whereas the opening of the posterior portion of the opening 294. would allow flexing of the sheath 290 for placement underneath the muscle. Further still, rather than trying to maneuver the sheaths 290 around the muscles, holes could be provided within the _18_ otherwise continuous sheaths 290. In this case, the muscles would need to be severed first to allow positioning of the sheaths, followed by reattachment of the muscles at positions corresponding to the holes. Regardless of the particular configuration, the embodiment illustrated in FIG. 14 allows multiple electrodes to be placed in contact with internal surface structures of the eye to facilitate indirect stimulation of the retina.
[0061] The embodiments of FIGs. 13 and 14 are particular examples of the schema illustrated in FIG. 15. Similar to the schemas illustrated in FIGS.
These devices typically employ arrays of stimulating electrodes powered by photodiodes or microphotodiodes disposed on the epiretinal side (the surface of the retina facing the vitreous cavity) or the subretinal side (the underneath side) of the neuroretina. For example, Chow et al. have described various designs for implants to be inserted in the sub-retinal space, i.e., a space created between the inner and outer retinal layers, in U.S. Patent I'los.
5,016,633; 5,024,223; 5,397,350; 5,556,423; 5,895,415; 6,230,057; 6,389,317 and 6,427,087. Generally, the implants described in fihese patents are placed in contact with the photoreceptor layer of the inner retina such that electrodes on the implants can provide stimulating currents, derived from the photovoltaic conversion ~f incident light, to the inner retina. additionally, technia;ues and devices f~r inserting such irnlalants int~ the scab-re~:ii~~l s~a~~e are ~Isc~
described in various ones ~f these patents, e.g., U.~. Pat. i~os. 5,016,633;
5,~2~4,~~3 and 6,389,3'i7.
(!~0~~] Cellular electrical signals also play important developmental roles, enabling nerve cells to develop and function properly. For example, nerve cells undergo constant remodeling, or "arborization", during development related to electric signaling. First an extensive preliminary network is formed that is then "pruned" and refined by mechanisms that include cell death, selective growth, loss of neurites (axonal and dendritic outgrowths), and the stabilization and elimination of synapses (Neely and Nicholls, 1995). If a neuron fails to exhibit or is inhibited from transducing normal electrical activity during arborization, axons fail to retract branches that had grown to inappropriate positions.
[0007] The application of electric currents to organ systems other than the eye is known to promote and maintain certain cellular functions, including bone growth, spinal cord growth and cochlear spiral ganglion cell preservation (Acheson et al., 1991; Dooley et al., 1978; Evans et al., 2001; Kane, 1988;
Koyama et al., 1997; Lagey et al., 1986; Leake et al., 1991; Leake et al., 1999; Politis and ~anakis, 1988a; Politis and Zanakis, 1988b; Politis and Zanakis, 1989; Politic et al., 1988a; Politis et al., 1988b).
[0008] In other studies, the application of growth and neurotrophic-type factors was found to promote and maintain certain retinal cellular functions.
For example, brain-derived neurotrophic factor (BDNF), neurotrophin-4. (NT-4), neurotrophin-5 (NT-5), fibroblastic growth factor (F~F) and glial cell line-derived neurotrophic factor (C~DNF) have been shown to enhanced neurite outgrowfih of retinal ganglion cells and to increase their survival in cell culture.
GDNF has been shown to preserve rod photoreceptors in the rd/rd mouse, an animal model of retinal degeneration. Nerve growth factor (NGF) injected into the intra-ocular area of the D3H mouse, also a model of retinal degeneration, results in a significant increase of surviving photoreceptor cells compared to controls (Eosco and Linden, 1999; Caleo et al., 1999; Carmignoto et al., 1989;
~'ui et al., 1998; Frasson et al., 1999; Lambiase and Aloe, 1990; I~eh et al., 1990). i~J~e~ methods or devices, I~owever, t~2 imlarc~~e'dhe gei-~er~~l inherent visual function of damaged retinal cells distant front a s~urce ~f electrical stim~alati~n through tl-~e use of cl-~r~nic electrical stimulation a~a~alied t~ t1 ~e neuroretina from either within tile eye ~r indirectly via contact with surface structures of the eye are known.
i3RIEF SUMMARY
[0009] The present invention provides techniques for preventive or therapeutic treatment of degenerative retinal disease through the application of electrical stimulation. In particular, the present invention concerns the use of electrical stimulation applied to surface structures of an eyeball for such treatment. Generally, this is achieved with a device comprising a source of an electrical stimulation signal coupled to a first electrode configured for contact with a first internal surface structure of an eyeball and a second electrode configured for contact with a second surface structure of the eyeball, which second surface structure may be external or internal. Surface structures of the eyeball may be categorized as either external surface structures (e.g., conjunctiva and cornea) or internal surface structures (e.g., sclera, episclera, intramuscular septum, Tenon's capsule, extraocular muscles or tendon, etc.).
The source of the electrical stimulation signal may be implemented internal to a body of a patient, external to the body or through a combined internal/external approach. Electrodes in accordance with various embodiments of the present invention may be arranged in one or more ring formations, including interleaved electrodes. The electrodes are preferably arranged such that a circuit created by the source, electrodes and intervening biological tissue provides traps-retinal electrical stimulation to thereby effect treatment.
SRIEF ~ESCRIPTI~~I ~F THE ~RAI~Ih~GS
E9~~ 0] FIG. ~ is a cross-sectional top view of a human eye.
[Q;~~~] FIG. ~ is a cr~ss-section thrczugh a htai~an eye indicating layers of the outer anal inner anatomical retina, as indicated by the inset of FIG.
'l.
[0~~ ~] FIG. ~ is a schematic bl~ch diagram ~f a prior art technique f~r indirect electrical stimulation.
[003] F1G. 4. is a schematic block diagram of another prior art technique for indirect electrical stimulation.
(0014] FIG. 5 is a schematic block diagram of yet another prior art technique for indirect electrical stimulation.
[0015] FIG. 6 is a schematic block diagram of a technique for indirect electrical stimulation in accordance with the present invention.
[0016] FIG. 7 is a schematic block diagram of another technique for indirect electrical stimulation in accordance with the present invention.
[0017] FIG. 8 is a partial cross-sectional side view of a human eye and surrounding structures.
[0018] FIG. 9 is a partial cross-sectional magnified view of a region of the eye illustrated in FIG. 8.
(0019] FIG. 10 is a side view of a human eye illustrafiing application of a corneal electrode in accordance with an embodiment of the present invention.
(0020] FIG. 11 is a side view of a human eye illustrating application of an epi-conjunctival electrode in accordance with an embodiment of the present invention.
[0021] FIG. 12 is a side view of a human eye illustrating application of a fiber electrode in a conjunctival fornix in accordance with an embodiment of the present invention.
[0022] FIG. 13 is a side view of a human eye illustrating application of a plurality of electrode arrays applied to an internal surface structure in accordance with an embodiment of the present invention.
[OO~~j FIG. °I~ is u~ ~id~ vie~,~ of a h~arna~~ e~~ illustrd~ii~~
appli~atioi~ on an electr~c~e array to an internal surface structure ire accorolance with an embodiment of the present inventi~n.
(~~2a~] Flt. 15 is a schematic block dia~qram of an internal surface structure/internal surface structure technique for indirect electrical stimulation in accordance with the present invention.
(0025] FIG. 16 is a schematic block diagram of an internal surface structure/exfiernal surface structure technique for indirect electrical stimulation in accordance with the present invention.
(0026] FIG. 17 is a top view of a human eye illustrating an exemplary implementation of the embodiment of FIG. 15.
(0027] FIG. 10 is a top view of a human eye illustrating a first exemplary implementation of the embodiment of FIG. 16.
(0025] FIG. 19 is a top view of a human eye illustrating a second exemplary implementation of the embodiment of FiG. 16.
DETAILED DESCRIPTI~N ~F THE
PRESENTLY PREFERRED EME~DIMENTS
(0029] In the course of testing for the safety and efficacy of retinal implants in humans blinded by retinitis pigmentosa, an unexpected and surprising observation was made: even though the implants were pieced at a discrete location in the subretinal space (acting as a prosthesis), vision was improved not only in those discrete locations as ea~pected, but also in distant locations of the retina. Thus chronic electrical stimulation in specific locations enhanced retinal cell function throughout the eye. This "halo effect" can be used to improve vision in those individuals who suffer from diseases, conditions and traumas that have damaged the outer retinal layer but leave the inner retinal layer at least partially intact. Although prosthetic electrical devices designed to replace damaged or missing retinal cells have been used to treat vision l~a~s caused I~a~r ~a~ater rel:inal degeneration, electrical ~,tirr~~alation t~ im~ar~ve large areas ~f retinal cell visual function is novel. s~s a non-Ilrr~ltinc~
ea~planation, the promoti~n of irnpr~ved retinal cell visual functi~n by chronic electrical stirnuiati~n rnGiy be e~zplained by the stin~~alation of pr~ad~acti~n and release of growth factors; more specifically, neurotrophic-type growth factors, by the stimulated retinas. The synthesis andlor secretion of neurotrophic factors would then improve retinal cell function and survival in conditions where these activities would be lost.
_5_ [0030] Accordingly, the present invention discloses both novel devices and methods to electrically stimulate the retina to improve large areas of retinal visual function and to protect the retina from degeneration. As described in greater detail below, the devices and methods disclosed herein may be generally categorized as indirect. Direct techniques involve stimulation of a retina wherein the stimulus traverses substantially no intervening biological structures. Conversely, indirect techniques encompass stimulation of a retina wherein the stimulus must traverse one or more intervening biological structures.
SubjectlPatient [0031] A subject (patient) may be a human being or a non-human animal, but is preferably a human. Usually the individual has suffered some type of retinal damage and/or degeneration that results in some degree of visual loss and/or has a condition that will result in retinal damage and/or degeneration. A normal (healthy) subject does not have a condition that will result in retinal damage and/or degeneration and/or has not suffered retinal damage and/or degeneration.
Irnpr~~ing visual fun~ti~~
[0032] Improving visual function refers to improving a targeted function of the eye, selected by the artisan, and includes improving any to all of the following capabilities of the eye, retina and visual system: perception of brightness in the presence of light, perception of darkness in the absence of li~~,hx, perc~laiions of con trust, oolor, sh~~p~ 7 res~al~ationY rnoa~emen t and visual field size.
[~~~3] Primary visual degradation means loss of ~eisua! functi~n due to malfuncti~ning, damaged ~r degenerati~n of structures found in tile eye.
Secondary visual degradation means loss of visual function glue t~ secondary damage, typically from lack of use of the vision-associated portions of the brain. Improving visual function means to improve the visual function of primary visual degradation, secondary visual degradation or both.
Eye%yeball [0034] The eye (or eyeball) has the usual definition in the art. Eye includes all interior and exterior surfaces, components, contents and cavities of the eye. The eye does not include the eyelid or optic nerve.
[0035] The retina of the eye can be divided into sectors as is commonly accepted in the art. Such sectors are described by the use of the terms temporal, nasal, superior, inferior, by clock hour designation, and by the number of degrees away from the macula. For example, the temporal sector of the retina is the retina temporal to a perpendicular plane cutting through retina from the 12 o'clock to the 6 o'clock positions and through the macula.
In another example, the superior sector is the retina superior to a perpendicular plane cutting through the 9 o'clock to 3 o'clock positions and through the macula. In a further example, the superior-temporal sector is the intersection of these two sectors, a pie-shaped area delineated from the 9 o'clock position of the peripheral retina to the macula and then clockwise to the 12 o'clock position. I~lore specific locations of the retina can be designated by degrees away from the macula and clock hour location: for example, ~0 degrees away from the macula at the 3 o'clock (nasal) position.
The number of degrees away from the macula is in visual axes degrees.
These axes all intersect through the lens of the eye.
(0036] The visual field sectors correspond oppositely to the retinal secfiors as is commonly understood in the art. For example, the superior-temporal sector of the retina corresponds to the inferior-nasal portion of the vis~a~l field.
Pe~i~~re6 ~1 [~0~~~] T~ lae ~aeripher~~l to an ob)ect, device ~r ~ther lanc~marl~ in eludes all surroun~9inc~ parts, but not the object, device or la~ldmarl~, i. e., the object, device or landmark, together with the peripheral portion, constitutes the whole.
Light (003] Light refers not only to the electromagnetic spectrum that humans can readily perceive visually (approximately 400 nm to 750 nm), but also includes ultraviolet light (<400 nm in wavelength) as well as infrared light (>750 nm in wavelength).
Indications (0039] The invention can be used to improve visual function in subjects in which the retina is damaged by disease, degeneration, condition, or trauma and/or to slow down or stop the progression of damage by disease, degeneration, condition or trauma. Common diseases, conditions, degeneration or trauma that are particularly amenable to this treatment include age-related macula degeneration, retinitis pigmentosa, Leber's congenital amaurosis, Stargardt's disease, best's disease, diabetic retinopathy, long-term retinal detachment, and choroidal damage.
~~e str~caetu~-~
(~04~] Deferring to the drawings, FIG. 1 illustrates a section through the eyeball. The neuroretina 150 comprises multiple layers of cells and structures (see FIG. 2). The photoreceptor components of the retina are situated within the neuroretina which covers the internal posterior cavity of the eye, terminating anteriorly at the ore serrate 167. The ciliary body 165 and the iris 162 are covered by extensions of the retina, lacking photoreceptor components. The outermost layers of the eye consist of the sclera 164 and corr~~~ ~ 155. The -c~(er~~ i~ ~~i~~r~'~~a l~az~ ~:h~~ eiiir~rgin~~ optics ne~~~e °i~a5. The: left 150 and vitreous cavity 154 are als~ indicated. The macula 15g of the retina is typically a ~ inm by 5 mm oval f-ec~i~t1, at the center of whicll is the fovea 170.
(~0~~~] The layers of the eye at the posterior p~le from inside to outside are shown in FIG. 2: internal limiting membrane 40, nerve fiber layer 42, ganglion cell layer 44, inner plexiform 46, inner nuclear layer 45, outer plexiform 50, outer nuclear cell layer 52, and photoreceptor outer and inner _g_ segment layer 54, all of which constitute the anatomical inner retinal layer, also known as the neuroretina 56. The retinal pigment epithelium 58 and Bruch's membrane 60 constitute the outer retinal layer 62. The choriocapiliaris 64 and choroid 66 comprise the choroidal vasculature 68. The outer coat of the eye is the sclera 70. Light 156 enters the retina as shown.
Indirect Stimulation [0042] In prior applications, I have disclosed embodiments possessing a common characteristic fihat the electrical stimulus is provided directly to the neuroretina, i.e., there are substantially no intervening biological structures.
In accordance with the present invention, electrical stimulus may be applied to the neuroretina in an indirecfi fashion, i.e., via one or more intervening biological structures.
[0043] Various methods for indirect stimulation, as that term is defined herein, are known. FIGS. 3-5 are schematic illustrations of such prior art techniques. FIG. 3 illustrates a technique (described in U.S. Patent No.
5,14.7,28q~ issued to Fedorov et al.; hereinafter "Fedorov") in which electrical stimulation is applied to an eye 204. of a patient 202 via a pair of surgically implanted electrodes 210, 212 applied to surfaces of the eye 204 and optic nerve 206. A source of electrical stimulation 208 is provided coupled to the pair of electrodes 210, 212. In practice, the source 208 comprises an induction coil that provides electrical currents as a result of magnetic fields applied to the temporal region of the patient 202. llVhile Fedorov reports improved vision in patients, the circumstances under which the patients were tr~~sue~3 ~r~. lira's I<~n~awf-~ ~n~1 ~3~a nc~~ ~~ape~r to h~~\A~ E~~~en s~a~~~~~~;,tv~-~ °~Ka p,w~Lr reviev~. i~ioreover, it will be reaelily evident to those having ordinary skill in the art that the implantati~n ~f an electrode in el~se pro~~imity t~ the ~ptic nerve 206 requires highly invasive and complicated surgery.
[0044] FIG. 4 illustrates a more recent technique proposed by Ghow in U.S. Patent No. 6,427,087. In particular, an electrode 210' is placed in contact with tissues of the eye 204, whereas another electrode 212' is placed within the vitreous cavity 205 that may be in confiact with the internal limiting membrane (see also the vitreous cavity 154 illustrated in FIG. 1). It is believed that the resulting traps-retinal stimulation resulting from this configuration will result in more efficient stimulation.
[0045] Yet another approach is illustrated in FIG. 5 in which the stimulating 210" and return 212" electrodes, rather than being in direct contact with the eye 204, are instead placed upon external tissues 214, 216.
Examples of this approach (sometimes referred to as microcurrent stimulation), particularly for the purpose of treating degenerative retinal diseases such as macular degeneration and retinitis pigmentosa, are taught in U.S. Patent No. 5,522,864 to Wallace et al. and U.S. Patent Nos. 6,035,236 and 6,275,735 to Jarding et al. Typically, the stimulating electrode 210" is coupled to external tissue in close proximity to the eye 204, e.g., the eyelid, and the return electrode 212" is coupled to distal external tissues such as the occipital lobe or arm of the patient 202. While anecdotal evidence of efficacy has been sporadically reported, no controlled, peer reviewed studies on humans are Known to have been performed and, furthermore, the American Academy of ~phthalmology's Taslc Force on Complementary Therapies concluded in September 2000 that "strong evidence has not been found to demonstrate the effectiveness of microcurrent stimulation treatment of [age-related macular degeneration] compared to standard therapies."
[0046] In contrast to the prior art techniques described above, the present invention encompasses indirect stimulation techniques based on application of one or more electrodes to surface structures of the eye, as opposed to peripheral structures such as the optic nerve or eyelids. ~s used herein, s~ai~face str~act~ar~os of the eye may be divided irn~ dw~a classes, internal surface structures and eazternal surface struet~ares as described in greater detail below. In general, surface str~act~ares of tile eye may he aiefirred as and of several laminae (taeginning most interi~rly with the sclera in the case ~f internal surface sfiructures) and forming or surrounding the eye, depending upon the specific region of the eye under consideration.
[0047] P, schematic illustration of an embodiment of indirect stimulation in accordance with the present invention is presented in FIG. 6. In this _11_ embodiment, at least one active or stimulating electrode 226 is applied to a surface structure of an eye 220. The at least one active electrode 226 is configured for chronic contact with the surface structure of the eye 220. As used herein, the term chronic encompasses not only continuous periods of time but also repetitive and/or periodic intervals of time. For example, fibs at least one active electrode 226 may be substantially permanently attached or otherwise coupled to the surface structure, or it may be configured to allow for repetitive placement in contact with, and subsequent removal from, the surface structure over a period of time established by a course of treatment.
At least one return or ground electrode 22~ is configured for application to tissues 222 substantially distant from the eyeball 220, e.g., outside the orbit of the eye. For example, in this embodiment, the at least one return electrode 22~ may be coupled to the temporal or occipital skull regions of the patient or, more distally, to the neck, shoulder, chest, arms or legs of the patient.
Additionally, the at least one return electrode 22~ may be configured for chronic or temporary application to the tissue 222. For example, the at least one return electrode 22~ may comprise one or more implantable electrodes substantially permanently coupled to the tissue 222 or it may comprise orle or more temporary cutaneous electrodes secured with an adhesive and electrically coupled using a suitable conductive gel. Positioned in this manner, and given the relatively low resistance of the vitreous relative to the surface structures and surrounding tissues of the eye, the active and ground return electrodes establish a traps-retinal circuit such that application of an electrical stimulation signal t~ the active electrode will result in beneficial traps-retinal c~arrei ~fds.
~~~a~~ In addition to the electr~des 226, 22~, the system illustrated in FI~. 0 also comprises a s~~arce of the electric al stirr~ulation sio~nal. The particular c~nfig~aration of the s~~aree depends on whether the source is implemented entirely internally or externally, or combined internally and externally, relative to the patient. For example, in the case where only the active electrode 226 is configured to removably contact external surface structures of the eye and the return electrode 2213 is configured for temporary _ ~2 _ cutaneous contact, the source may comprise one or more input terminals 224 for application of the electrical stimulation signal to the electrodes. In this case, the electrical stimulation signal is provided by an extraocular signal source 224'.
[0049] Alternatively, the source 224' may be entirely internal to the patient 202' as in the case of an implantable battery and, optionally, signal generation circuitry (not shown). In this case, it is assumed that the at least one return electrode 220 is likewise chronically implanted in the patient 202', thereby vitiating the need for any input terminals 224.
[0050] Further still, the source may be implemented as a combination of internal 224' and external 224" (relative to the patient) components. For example, the internal source component 224' may comprise a receiver induction coil implanted subcutaneously and the external source component 224" may comprise transmitting coil that may be precisely aligned with the receiver induction coil. As known in the art, such transmitter/receiver coil pairs may be used to transmit power and data that may be used to provide the electrical stimulation signal.
[00~~] In practice, the electrical stimulation signal provided by the source may comprise virtually any type of waveform demonstrating a beneficial effect. For example, the electrical stimulation signal may comprise an anodic or cathodic direct current signal or a time-varying waveform such as a square, sine, triangular, saw tooth signal or any other similar waveform.
Preferably, the electrical stimulation signal comprises a bi-phasic waveform that is balanced in the sense a net zero charge is applied to the retina over a perioc9 a~f tune. Ti its may be e~chieved, bar v~eay of n on-e~~ha~as,tive e~aarnteles, through r~l~re use of a signal cornprisine~ a continuous train of equal-duratiorl &ai-phasic pulses; eqr,aal-ol~aration tai-phaeic pulses separater2 by peri~ds of quiescence; varying duration and amplitude bi-phasic, charge balanced pulses; combinations of the above; etc. Pulse frequencies may range anywhere from 10 KH~ down to 0.001 Hz or, in the extreme, even a continuous monophasic waveform, i.e., 0 H~. Those having ordinary skid in the art will appreciate that the particular type of electrical stimulation signal _ 1~ _ used is a matter of design choice and is selected so as to provide maximum beneficial effect.
[0052] A schematic illustration of another embodiment of indirect stimulation in accordance with the present invention is presented in FIG. 7.
In this embodiment, the at least one active electrode 226 is applied to a first surface structure of the eye 220 and the at least one return electrode 228 is applied to a second surface structure of the eye 220. In practice, the first and second surface structures may be the same or different surface structures.
The source 224, 224', 224" of the electrical stimulation signal in this embodiment may comprise any of the alternatives described above relative to FIG. 6. Pt is anticipated that the embodiment of indirect stimulation illustrated in FIG. 7 will provide heightened stimulation of the retina given the relative proximity of electrodes to the retina. The various surface structures applicable to the present invention are further described below with reference to FIGs. 8 and 9.
[~0~3] E~eferring now to FIG. 8, an eye and surrounding structures are illustrated. The ocular orbit is defined by bone structures 230, 231. V~ithin the orbit, a layer of extraconal fat 233 and intraconal fat 235 surround the eyeball.
The fat layers 233, 235 are separated from each other by a cone defined by superior 236, inferior 238 and lateral 240 extraocular muscles as well as an intermuscular septum 242 connecting fibs muscles. The optic nerve 166 exits the orbit posteriorly, whereas the anterior portion of the eyeball is formed by a portion of the sclera and the cornea 158. The so-called Tenon's capsule 24.4 (partially shoevn) separates the eyeball from the orbital fat and forms a socleet witPlin whicPl the eyeball moves. The upper and laar~er eyelids 245, 24 i enclose and protect the anterior portion of the eyeball. The conjunctiva c~mprises the bulbar con junctiva 150' overlying the anterior pcarti~n ~f the sclera and the palpebral conjunctiva 15g" overlying the Pnner surface ~f the upper and lower eyelids 246, 247. The fold between the bulbar and palpebral conjunctiva 159', 159" gives rise to a conjunctival fornix 250. In the context of the present invention, external surface structures comprise those surface structures that are accessible via the palpebral fissure defined by the eyelids, _ 1 Q. _ i.e., the cornea 158 and the conjunctiva 159. Internal surface structures are defined as those surface structures posterior to the bulbar conjunctiva 159' and comprise the various laminae beginning with the sclera and its overlying structures, which overlying structures are dependent upon the particular region of the eyeball under consideration.
[0Q54] FIG. 9 schematically illustrates the various surface structures present at the exemplary region indicated in FIG. 8. The dimensions shown are not to scale. The sclera 164 forms the innermost surface structure.
Moving outwardly from the sclera 164, the episclera 260 is a thin, loose layer of connective tissue forming the outer surtace of the sclera 164. The intermuscular septum 242 resides above the episclera 260, and Tenon's capsule 244 resides above the intermuscular septum 242. Each of the layers illustrated in FIG. 14 comprises, for purposes of the instant invention, a separate surface structure to which an electrode may be applied. Those having ordinary sfcill in the art will appreciate that other regions of the eyeball may have surfiace structure layers different from those illustrated in FIG. 9.
[005~~ carious exemplary implementations of the embodiments of FIGS. 6 and 7 are schematically illustrated with respect to FIGS. 10-14~. For reference, each of FIGs. 10-12 illustrate the superior 236, inferior 238 and lateral 240 extraocular muscles, the upper and lower eyelids 246, 247 and the cornea 158. FIG. 10 illustrates an embodiment in which a contact lens body 265 supports one or more corneal electrodes 266. Various materials for fabricating the supporting body 265 and the at least one corneal electrode 266 are l5nown to those having ordinary shill in the art. ~Ithough it is preferred that the at least one corneal electrode 266 C~ae employed as an active elects or~le, it may likewise be employed as a return electrode. (This is also true of the rather embo~linlents illustrated in FIGS. 11 and 12.j The at least one corn cal elects°ode 266 may comprise a plurality of discrete electrodes arranged, for example, in a ring formation affi~ced in proximity to the periphery of the supporting body 265, or may comprise a single annular electrode similarly affixed to the supporting body 265. Alternatively, the at least one corneal electrode 266 may be arranged closer to the centre! region of the cornea.
_15_ Where a plurality of electrodes 266 are employed, each electrode may be individually selectable, i.e., each of the electrodes is separately addressable and the electrical stimulation signal may be applied to each electrode individually. When the electrical stimulation signal is applied, current will flow through the cornea and vitreous cavity, across the retina and back to the return electrode. Note that, for ease of illustration, none of FIGs. 10-12 illustrate the complementary electrode, nor do FIGs. 10-14 illustrate the electrical connections between the electrodes and the source of the electrical stimulation signal, which connections will be readily devisable as a matter of design choice by those having ordinary skill in the art.
[0056] FIG. 11 illustrates another embodiment in which an annular supporting body 270 provides support for at least one epi-conjunctiva) electrode 271. ~nce again, various materials for fabricating the supporting body 270 and the at least one epi-conjunctiva) electrode 271 are known to those having ordinary skill in the art. As in the embodiment of FIG. 10, the at least one epi-conjunctiva) electrode 271 may comprise a plurality of individually selectable electrodes or a single annular electrode as a matter of design choice. In the example shown in FIG. 11, the at least one epi-conjunctival electrode 271 contacts the bulbar conjunctiva 159' in close proximity to the cornea 158. However, additionally or alternatively, the at least one epi-conjunctiva) electrode 271 may be placed more distally from the cornea 158 and yet still in contact with the bulbar conjunctiva 159'.
Regardless, current flow will traverse the bulbar conjunctiva 159', the sclera, vitreous cavity and retina.
[~9~~7] FIG. °I2 illustrates yet ane~ther emb~dir~lent in which an electrode 275 is placed in epi-conjunctiva) contact v~ithin the conjunctiva) fornix 250.
In practice, the electrode 275 may comprise a fibrous or filamentary electrode such as a "~TL" electrode. ~TL electrodes are particularly advantageous because they are known to be well tolerated by patients given their relatively slender dimensions. Although a single electrode is illustrated in the lower conjunctiva) fornix 250, an electrode may also be placed in the upper conjunctiva) fornix as an alternative, or in addition to, the lower electrode.
_15_ Furthermore, more than one electrode can be placed into either of the fornices at a single time. As in the embodiment of FIG. 11, current flow in the embodiment of FIG. 12 will traverse the bulbar conjunctiva 159', the sclera, vitreous cavity and retina.
[005~J Each of FIGs. 10-12 illustrates embodiments in which electrodes are placed in contact with external surface structures of the eye. FIG. 73 schematically illustrates an embodiment in which electrodes are applied to internal surface structures. In particular, one or more supporting rings 281-283 are implanted in contact with internal surface structures. Note that although the third ring 283 is placed in contact with a substantially anterior portion of the eye, it is implanted beneath the bulbar conjunctiva 159'.
However, a hybrid internaUexternal surface structure technique may be possible if the third ring 283 were placed above the bulbar conjunctiva 159' in a manner similar to that illustrated in FIG. 11. (Such hybrid arrangements are further described with reference to FIGS. 16, 18 and 19 below.) Techniques for introducing such rings into the orbit and for securing them to the eye are know in the art, particularly from the use of so-called scleral buckles. For example, each ring may be sutured in place in accordance with such techniques. Note that the first and second rings 281, 282 are preferably placed beneath the extraocular muscles 236, 238, 240 in accordance with known techniques.
[0059] Each ring comprises at least one electrode 285 and, in a preferred embodiment, each ring comprises a plurality ofi electrodes. Suitable materials for fabricating the supporting rings and electrodes are known to those i~tavitlg ordinary shill in the art. Preferably, each electrode is individually selectable. Additi~tlally, each individual electrode may be electrically c~nfigured to act as an active elecvr~ade ~r a return electrode. In this rnanner, each ring 28'i-283 may comprise both active and return electrodes. Irr such an embodiment, it may be preferable to interleave active and return electrodes and, further, to antipodally arrange the active and return electrodes. An antipodal arrangement of electrodes will give rise to a trans-retina! current path that is substantially perpendicular to the retinal surface.
_17_ Additionally, being individually selectable, each electrode in an antipodal electrode pair could be periodically switched between active and return operation. Further still, electrodes between rings could be activated as stimulating pairs, e.g., an electrode from a first ring 281 could be operated as an active electrode and an electrode from a second ring 282 could be operated as a return electrode, and vice versa. Although a specific number of supporting rings 281-283 positioned in substantially vertical orientations are illustrated in FIG. 13, it is understood that a greater or lesser number of such rings could be employed and, further, that the orientation of such rings need not be limited to substantially vertical. Taken to an extreme, the supporting rings 281-283 could be eliminated and, instead, each electrode 285 may comprise a separate, independent supporting member such that individual electrodes may be implanted at specific locations on specific internal surface structures.
[0060] Yet another embodiment providing contact with internal surface structures is illustrated in FIG. 14. In this embodiment, one or more supporking sheaths 290 comprising a plurality of electrodes 292 are positioned and secured in contact with internal surface structures of the eye. The discussion above with regard to individually selectable and antipodal electrodes relative t~ FIG. 13 equally applies to the arrangement of FIG. 1.4.
To accommodate the presence of various ocular structures, such as the connections between the various muscles 236, 238, 2~0 and the sclera, openings 294 may be provided. In the example illustrated in FIG. 14, a plurality of sheaths 290 are provided such that each sheath 290 covers the surfaces between ac9)acent muscles wi°dl ~ the ~pei ~ii~gs 29~ thereby being formed by the ad)acency of the sheaths 290 when implanted. In the case where a ~,ingle sheath 290 surrounds at least one of the muscles, the ar~tm-i~r portion o~~ the rapening 29q~ could be fabricated such that a unitary body is provided (illustrated with dotted lines) whereas the opening of the posterior portion of the opening 294. would allow flexing of the sheath 290 for placement underneath the muscle. Further still, rather than trying to maneuver the sheaths 290 around the muscles, holes could be provided within the _18_ otherwise continuous sheaths 290. In this case, the muscles would need to be severed first to allow positioning of the sheaths, followed by reattachment of the muscles at positions corresponding to the holes. Regardless of the particular configuration, the embodiment illustrated in FIG. 14 allows multiple electrodes to be placed in contact with internal surface structures of the eye to facilitate indirect stimulation of the retina.
[0061] The embodiments of FIGs. 13 and 14 are particular examples of the schema illustrated in FIG. 15. Similar to the schemas illustrated in FIGS.
6 and 7, the schema of FIG. 15 comprises a source 224, 224', 224" coupled to electrodes 226, 228 in contact with an eye 220. However, in this schema, the electrodes are both in contact with internal surface structures 300, 302 of the eye. In a presently preferred embodiment, the electrodes 226, 228, being configured for contact with internal surface structures, are preferably configured for chronic implantation, e.g., constructed of materials exhibiting very good biodurability, biocompatibility, etc.
[0062] A further schema (generalising the "hybrid" embodiment mentioned above with regard to FIG. 13) is illustrated in FIG. 16. The schema of FIG. 16 differs from that ofi FIG. 15 in that one electrode 228 is configured for contact with an external surfiace structure 304 while the other electrode 226 is configured for contact with an internal surface structure 300. ~nce again, electrodes 226 configured for contact with internal surface structures are preferably configured for chronic implantation. In contrast, those electrodes 228 configured for contact with external surface structures may be configured for chronic or acute (i.e., removable) contact. For the embodirnents illustrated in FIGs. 15 and 1C~, as in all ~arevi~aus em~aodimcn'ds, the electrodes 22G, 228 may each comprise a plurality of separately selectable elc~ctro~9es each of which may be alternated betc~een stirnulating and return electrode functionality. Particular implementations of the schemes of FIGS. 15 and 16 are further illustrated in FIGS. 17-19. For reference, each of FIGs. 17-19 illustrate a top view of an eyeball comprising a cornea 158, conjunctiva 159, sclera 164 and, in hidden view, a neuroretina 150, macula 169 and optic nerve 166.
_ 1g _ [0063] Referring now to FIG. 17, an exemplary embodiment of the schema of FIG. 15 is illustrated. In particular, FIG. 17 illustrates the placement of a first electrode 310 (in this case, a plurality of electrodes) placed on a first internal surface structure and a second electrode 320 on a second internal surface structure. Connections to an electrical source 324 are schematically shown. In this embodiment, the first and second internal surface structures may comprise, for example, separate regions of sclera) tissue. As shown, the plurality of electrodes 310 constituting the first electrode is supported by a body member 322 in the form of a sclera) band or ring, as described previously with reference to FIG. 13. The second electrode 320, although illustrated as a single electrode, may comprise a plurality of electrodes. In either case, the second electrode 320 may include a supporting body member (not shown) to aid in positioning and fixation of the second electrode. Applying an electrical stimulation signal across the first and second electrodes will result in traps-retinal currents that stimulate the retina.
To maximize the effects ofi traps-retinal current, the second electrode 320 is preferably configured for and positioned upon an internal surface structure corresponding to (i.e., aligned with) the macula 169 of the eye.
[0064] Referring now to FIGS. 13 and 19, exemplary embodiments of the schema of FIG. 16 are illustrated. FIG. 18 illustrates placement of a second electrode 320 (as described above relative to FIG. 17) on an internal surface structure of the eye. However, in this embodiment, the first electrode 330 is configured for epi-conjunctiva) placement, i.e., in contact with an e~sternal surface structure. As shown, the first electrode may comprise a supporting body member 332 as described previ~ausly v~ith reference t~ FIG.
11. FIG. 19 illustrates yet another internal/external s~ariace structure err~b~dirnent combining a sclera) ring elects°~ole 310 implementation and an epi-oonjunctival electrode 330 implementation.
,Eqrai~alents [0065] Although particular embodiments have been disclosed herein in detail, this has been done for purposes of illustration only and is not intended to be limiting with respect to the scope of the appended claims that follow.
In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. Other aspects, advantages, and modifications are considered to be within the scope of the following claims.
[0062] A further schema (generalising the "hybrid" embodiment mentioned above with regard to FIG. 13) is illustrated in FIG. 16. The schema of FIG. 16 differs from that ofi FIG. 15 in that one electrode 228 is configured for contact with an external surfiace structure 304 while the other electrode 226 is configured for contact with an internal surface structure 300. ~nce again, electrodes 226 configured for contact with internal surface structures are preferably configured for chronic implantation. In contrast, those electrodes 228 configured for contact with external surface structures may be configured for chronic or acute (i.e., removable) contact. For the embodirnents illustrated in FIGs. 15 and 1C~, as in all ~arevi~aus em~aodimcn'ds, the electrodes 22G, 228 may each comprise a plurality of separately selectable elc~ctro~9es each of which may be alternated betc~een stirnulating and return electrode functionality. Particular implementations of the schemes of FIGS. 15 and 16 are further illustrated in FIGS. 17-19. For reference, each of FIGs. 17-19 illustrate a top view of an eyeball comprising a cornea 158, conjunctiva 159, sclera 164 and, in hidden view, a neuroretina 150, macula 169 and optic nerve 166.
_ 1g _ [0063] Referring now to FIG. 17, an exemplary embodiment of the schema of FIG. 15 is illustrated. In particular, FIG. 17 illustrates the placement of a first electrode 310 (in this case, a plurality of electrodes) placed on a first internal surface structure and a second electrode 320 on a second internal surface structure. Connections to an electrical source 324 are schematically shown. In this embodiment, the first and second internal surface structures may comprise, for example, separate regions of sclera) tissue. As shown, the plurality of electrodes 310 constituting the first electrode is supported by a body member 322 in the form of a sclera) band or ring, as described previously with reference to FIG. 13. The second electrode 320, although illustrated as a single electrode, may comprise a plurality of electrodes. In either case, the second electrode 320 may include a supporting body member (not shown) to aid in positioning and fixation of the second electrode. Applying an electrical stimulation signal across the first and second electrodes will result in traps-retinal currents that stimulate the retina.
To maximize the effects ofi traps-retinal current, the second electrode 320 is preferably configured for and positioned upon an internal surface structure corresponding to (i.e., aligned with) the macula 169 of the eye.
[0064] Referring now to FIGS. 13 and 19, exemplary embodiments of the schema of FIG. 16 are illustrated. FIG. 18 illustrates placement of a second electrode 320 (as described above relative to FIG. 17) on an internal surface structure of the eye. However, in this embodiment, the first electrode 330 is configured for epi-conjunctiva) placement, i.e., in contact with an e~sternal surface structure. As shown, the first electrode may comprise a supporting body member 332 as described previ~ausly v~ith reference t~ FIG.
11. FIG. 19 illustrates yet another internal/external s~ariace structure err~b~dirnent combining a sclera) ring elects°~ole 310 implementation and an epi-oonjunctival electrode 330 implementation.
,Eqrai~alents [0065] Although particular embodiments have been disclosed herein in detail, this has been done for purposes of illustration only and is not intended to be limiting with respect to the scope of the appended claims that follow.
In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. Other aspects, advantages, and modifications are considered to be within the scope of the following claims.
Claims (13)
1. A device for treatment of degenerative retinal disease, comprising:
a source of electrical stimulation;
a first electrode, coupled to the source, configured for contact with a first internal surface structure of an eyeball; and a second electrode, coupled to the source, configured for contact with a second surface structure of the eyeball;
wherein the second electrode is configured for contact with an external surface structure of the eyeball or an internal surface structure of the eyeball corresponding to a macula of the eyeball or an internal surface structure of the eyeball being an outer surface of a sclera of the eyeball, wherein the first electrode is at least one stimulating electrode configured for chronic contact with the first surface structure of the eyeball, and wherein the second electrode is at least one return electrode configured for chronic contact with the second surface structure of the eyeball.
a source of electrical stimulation;
a first electrode, coupled to the source, configured for contact with a first internal surface structure of an eyeball; and a second electrode, coupled to the source, configured for contact with a second surface structure of the eyeball;
wherein the second electrode is configured for contact with an external surface structure of the eyeball or an internal surface structure of the eyeball corresponding to a macula of the eyeball or an internal surface structure of the eyeball being an outer surface of a sclera of the eyeball, wherein the first electrode is at least one stimulating electrode configured for chronic contact with the first surface structure of the eyeball, and wherein the second electrode is at least one return electrode configured for chronic contact with the second surface structure of the eyeball.
2. The device of claim 1, wherein the first electrode is configured for contact with the internal surface structure of the eyeball corresponding to the macula of the eyeball.
3. The device of the claim 1, further comprising a body member supporting the first electrode.
4. The device of claim 1, further comprising a body member supporting the second electrode.
5. The device of claim 1, wherein an electrical stimulation signal from the source is applied to the eyeball via the at least one stimulating electrode and the at least one return electrode.
6. The device of any one of claims 1 to 5, wherein the second electrode is configured for contact with the external surface structure of the eyeball.
7. The device of claim 1, wherein the second electrode is supported on a body member configured for attachment to the outer surface of the sclera.
8. The device of claim 7, wherein the body member comprises a band, a ring or a sheath which is configured to extend at least partially around the eyeball to aid in positioning and fixation of the second electrode.
9. The device of claim 8, wherein the body member includes one or more openings to accommodate the presence of ocular structures.
10. The device of claim 9, wherein the ocular structures comprise connections between muscles and the sclera.
11. The device of any one of claims 1 to 10, wherein the first electrode is supported on a body member configured for contact with an internal surface structure corresponding to a macula of the eyeball.
12. The device of claim 1, wherein the second electrode is supported on a body member configured for contact with an external surface structure of the eyeball, wherein the contact is corneal or epi-conjunctival contact with the external surface structure of the eyeball.
13. The device of any one of claims 1 to 12, wherein the first electrode and the second electrode are electrically interconnected via a wire.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/606,117 | 2003-06-24 | ||
US10/606,117 US20040106965A1 (en) | 2001-06-29 | 2003-06-24 | Methods and apparatus for treatment of degenerative retinal disease via indirect electrical stimulation |
US10/863,519 | 2004-06-09 | ||
US10/863,519 US20050004625A1 (en) | 2001-06-29 | 2004-06-09 | Treatment of degenerative retinal disease via electrical stimulation of surface structures |
PCT/US2004/018606 WO2005004985A2 (en) | 2003-06-24 | 2004-06-10 | Device for treatment of degenerative retinal disease via electrical stimulation of surface stuctures of the eyeball |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2530171A1 CA2530171A1 (en) | 2005-01-20 |
CA2530171C true CA2530171C (en) | 2013-07-23 |
Family
ID=34068494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2530171A Expired - Fee Related CA2530171C (en) | 2003-06-24 | 2004-06-10 | Treatment of degenerative retinal disease via electrical stimulation of surface structures |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050004625A1 (en) |
EP (1) | EP1635906B2 (en) |
JP (1) | JP4654182B2 (en) |
AU (1) | AU2004255156C1 (en) |
CA (1) | CA2530171C (en) |
ES (1) | ES2385809T5 (en) |
WO (1) | WO2005004985A2 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050033202A1 (en) * | 2001-06-29 | 2005-02-10 | Chow Alan Y. | Mechanically activated objects for treatment of degenerative retinal disease |
US20050004625A1 (en) † | 2001-06-29 | 2005-01-06 | Chow Alan Y. | Treatment of degenerative retinal disease via electrical stimulation of surface structures |
US20080077192A1 (en) * | 2002-05-03 | 2008-03-27 | Afferent Corporation | System and method for neuro-stimulation |
JP4204066B2 (en) * | 2002-12-05 | 2009-01-07 | 保雄 田野 | Artificial vision system |
JP2007521124A (en) * | 2004-02-06 | 2007-08-02 | シフィックス リミテッド ライアビリティ カンパニー | Treatment of visual impairment using at least one of electrical energy, light energy, and acoustic energy |
AU2004226908B2 (en) * | 2004-11-02 | 2006-09-14 | Sydney Biotech Pty Ltd | Extraocular device |
EP1652552B1 (en) * | 2004-11-02 | 2008-09-17 | Sydney Biotech Pty. Ltd. | Extraocular device |
WO2006118679A2 (en) * | 2005-04-28 | 2006-11-09 | Second Sight Medical Products, Inc. | Package for an implantable neural stimulation device |
US8460351B2 (en) | 2005-08-05 | 2013-06-11 | Gholam A. Peyman | Methods to regulate polarization and enhance function of excitable cells |
US8562660B2 (en) | 2005-08-05 | 2013-10-22 | Gholam A. Peyman | Methods to regulate polarization and enhance function of excitable cells |
US8409263B2 (en) * | 2005-08-05 | 2013-04-02 | Gholam A. Peyman | Methods to regulate polarization of excitable cells |
US10022457B2 (en) | 2005-08-05 | 2018-07-17 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
US9962558B2 (en) | 2005-08-05 | 2018-05-08 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
EP2520331A3 (en) | 2006-04-12 | 2013-02-20 | Proteus Digital Health, Inc. | Void-free implantable hermetically sealed structures |
WO2009006636A2 (en) * | 2007-07-05 | 2009-01-08 | Second Sight Medical Products | Return electrode for a flexible circuit electrode array |
JP5284014B2 (en) * | 2008-09-02 | 2013-09-11 | 株式会社ニデック | Visual reproduction assist device |
US20100241060A1 (en) * | 2009-03-18 | 2010-09-23 | Roizman Keith | Surgical devices and methods |
US20120083861A1 (en) * | 2010-10-04 | 2012-04-05 | The General Hospital Corporation | Selective activation of neurons by sinusoidal electric stimulation |
CN103313754B (en) | 2010-11-16 | 2015-09-30 | 小利兰·斯坦福大学理事会 | Be used for the treatment of the system and method for xerophthalmia |
US9821159B2 (en) | 2010-11-16 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Stimulation devices and methods |
EP2686062A4 (en) * | 2011-03-18 | 2014-09-10 | Salk Inst For Biological Studi | Method for identification of retinal cell types using intrinsic properties |
CN104780970B (en) * | 2012-06-29 | 2019-08-13 | 庄臣及庄臣视力保护公司 | The method and Ophthalmoligic instrument that electric current for eyes heals |
US9717627B2 (en) | 2013-03-12 | 2017-08-01 | Oculeve, Inc. | Implant delivery devices, systems, and methods |
US10155108B2 (en) | 2013-04-19 | 2018-12-18 | Oculeve, Inc. | Nasal stimulation devices and methods |
US9990861B2 (en) | 2013-05-28 | 2018-06-05 | Pixium Vision | Smart prosthesis for facilitating artificial vision using scene abstraction |
JP6604963B2 (en) | 2014-02-25 | 2019-11-20 | オキュリーブ, インコーポレイテッド | Polymer formulations for nasolacrimal gland stimulation |
DK3171928T3 (en) | 2014-07-25 | 2020-05-18 | Oculeve Inc | STIMULATION PATTERNS FOR TREATMENT OF DRY EYES |
US9764150B2 (en) * | 2014-10-22 | 2017-09-19 | Oculeve, Inc. | Contact lens for increasing tear production |
EP3721938A1 (en) | 2014-10-22 | 2020-10-14 | Oculeve, Inc. | Stimulation devices and methods for treating dry eye |
US11419543B1 (en) | 2016-03-03 | 2022-08-23 | Gholam A. Peyman | Early disease detection and therapy |
WO2017066620A1 (en) * | 2015-10-16 | 2017-04-20 | Rynerson James M | Energetic device for treating an eye disorder |
US10426958B2 (en) | 2015-12-04 | 2019-10-01 | Oculeve, Inc. | Intranasal stimulation for enhanced release of ocular mucins and other tear proteins |
US10300121B2 (en) | 2015-12-21 | 2019-05-28 | Gholam A. Peyman | Early cancer detection and enhanced immunotherapy |
US11660229B2 (en) | 2015-12-21 | 2023-05-30 | Gholam A. Peyman | Cancer treatment methods using thermotherapy and/or enhanced immunotherapy |
US11090385B2 (en) | 2015-12-21 | 2021-08-17 | Gholam A. Peyman | Early cancer detection and enhanced immunotherapy |
US9849092B2 (en) | 2015-12-21 | 2017-12-26 | Gholam A. Peyman | Early cancer detection and enhanced immunotherapy |
US10136820B2 (en) | 2015-12-21 | 2018-11-27 | Gholam A. Peyman | Method to visualize very early stage neoplasm or other lesions |
US11433260B2 (en) | 2015-12-21 | 2022-09-06 | Gholam A. Peyman | Cancer treatment methods using thermotherapy and/or enhanced immunotherapy |
US10252048B2 (en) | 2016-02-19 | 2019-04-09 | Oculeve, Inc. | Nasal stimulation for rhinitis, nasal congestion, and ocular allergies |
US10376600B2 (en) | 2016-03-03 | 2019-08-13 | Gholam A. Peyman | Early disease detection and therapy |
US11007367B2 (en) | 2016-03-16 | 2021-05-18 | Nova Oculus Canada Manufacturing Ulc | Microcurrent device for the treatment of visual disease |
EP3452166A4 (en) | 2016-05-02 | 2019-12-18 | Oculeve, Inc. | Intranasal stimulation for treatment of meibomian gland disease and blepharitis |
RU2019118600A (en) | 2016-12-02 | 2021-01-11 | Окулив, Инк. | APPARATUS AND METHOD FOR MAKING DRY EYE SYNDROME PREDICTION AND TREATMENT RECOMMENDATIONS |
TWI686223B (en) | 2017-05-02 | 2020-03-01 | 加拿大商諾瓦眼部加拿大製造無限責任公司 | Direct electrical stimulation delivery system for the treatment of visual disease |
EP3860703A1 (en) | 2018-10-01 | 2021-08-11 | Biovisics Medical, Inc. | System and methods for controlled electrical modulation for vision therapy |
US11305118B2 (en) | 2018-11-30 | 2022-04-19 | Biovisics Medical, Inc. | Head worn apparatuses for vision therapy |
WO2020210471A1 (en) | 2019-04-10 | 2020-10-15 | Biovisics Medical, Inc. | Systems and interfaces for ocular therapy |
US11511112B2 (en) | 2019-06-14 | 2022-11-29 | Biovisics Medical, Inc. | Wearable medical device |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US793004A (en) * | 1904-07-23 | 1905-06-20 | Frank Howard May | Eye-massage machine. |
US1684860A (en) * | 1927-03-12 | 1928-09-18 | De Forest B Catlin | Eye-treating apparatus |
US2525381A (en) * | 1947-09-25 | 1950-10-10 | Tower Paul | Contact-type electrode holder |
US2721316A (en) * | 1953-06-09 | 1955-10-18 | Joseph D Shaw | Method and means for aiding the blind |
US2760483A (en) * | 1953-10-29 | 1956-08-28 | Tassicker Graham Edward | Retinal stimulator |
US3320947A (en) * | 1963-10-25 | 1967-05-23 | Knoll Max Hans | Device for the excitation of nerve networks |
US3594823A (en) * | 1969-02-11 | 1971-07-27 | Patent Management Inc | Visual substitution system with receptor scanning means |
US3628193A (en) * | 1969-02-19 | 1971-12-21 | Inst Of Medical Sciences The | Tactile image projection system |
GB1319774A (en) * | 1969-06-26 | 1973-06-06 | Nat Res Dev | Visual prosthetic device |
US3995635A (en) * | 1971-09-09 | 1976-12-07 | Alza Corporation | Ocular insert |
US3766311A (en) * | 1972-04-26 | 1973-10-16 | H Boll | Sensory substitution system |
US3893444A (en) * | 1972-07-20 | 1975-07-08 | Univ California | Non-invasively measuring arterial oxygen tension |
US3769961A (en) * | 1972-07-20 | 1973-11-06 | I Fatt | Conjunctival device |
US3848608A (en) * | 1973-07-23 | 1974-11-19 | Gen Electric | Subject integument spatial stimulator |
US3998659A (en) * | 1974-01-28 | 1976-12-21 | Texas Instruments Incorporated | Solar cell with semiconductor particles and method of fabrication |
US3914800A (en) * | 1974-06-06 | 1975-10-28 | Inst Of Medical Sciences | Fluid mechanical tactile oscilloscope to augment the five senses |
US4001867A (en) * | 1974-08-22 | 1977-01-04 | Dionics, Inc. | Semiconductive devices with integrated circuit switches |
US4018218A (en) * | 1975-03-12 | 1977-04-19 | Carlson James E | Method and apparatus for sleep induction |
US4089329A (en) * | 1976-03-18 | 1978-05-16 | University Of Utah Research Institute | Noninvasive, continuous intraocular pressure monitor |
FR2379085A1 (en) * | 1977-01-31 | 1978-08-25 | Comp Generale Electricite | HIGH-SPEED ELECTRO-OPTICAL SHUTTER |
US4326529A (en) * | 1978-05-26 | 1982-04-27 | The United States Of America As Represented By The United States Department Of Energy | Corneal-shaping electrode |
US4251887A (en) * | 1979-04-02 | 1981-02-24 | Anis Aziz Y | Posterior chamber capsular lens implant and method for implantation of the lens |
US4272910A (en) * | 1979-07-31 | 1981-06-16 | Danz W R | Ocular prosthetic or the like |
US4271841A (en) * | 1980-01-31 | 1981-06-09 | Medtronic, Inc. | Electro-ocular stimulation system |
US4484922A (en) * | 1981-06-25 | 1984-11-27 | Rosenwald Peter L | Occular device |
US4551149A (en) * | 1982-02-16 | 1985-11-05 | Michael Sciarra | Prosthetic vision system |
US4600004A (en) * | 1982-09-08 | 1986-07-15 | Osvaldo Lopez | Intraocular lens holder and inserter |
US4524776A (en) * | 1983-10-27 | 1985-06-25 | Withers Stanley J | Split carrier for eyelid sensor and the like |
US4614193A (en) * | 1984-01-09 | 1986-09-30 | Pain Suppression Labs, Inc. | Electronic glaucoma treatment apparatus and methodology |
US4601545A (en) * | 1984-05-16 | 1986-07-22 | Kern Seymour P | Variable power lens system |
US4664117A (en) * | 1984-10-09 | 1987-05-12 | Beck Stephen C | Apparatus and method for generating phosphenes |
US4603697A (en) * | 1985-01-07 | 1986-08-05 | William Kamerling | System for preventing or treating open angle glaucoma and presbyopia |
GB8513192D0 (en) * | 1985-05-24 | 1985-06-26 | British Telecomm | Optical logic devices |
US4667676A (en) * | 1985-06-17 | 1987-05-26 | Audimax, Inc. | Method of evaluating the vestibular system |
US4628933A (en) * | 1985-07-23 | 1986-12-16 | Michelson Robin P | Method and apparatus for visual prosthesis |
US4750498A (en) * | 1986-02-21 | 1988-06-14 | Coopervision, Inc. | Method and tool for inserting an intraocular lens |
US4679572A (en) * | 1986-03-11 | 1987-07-14 | Intermedics, Inc. | Low threshold cardiac pacing electrodes |
JPS62179601U (en) * | 1986-04-30 | 1987-11-14 | ||
GB8612537D0 (en) * | 1986-05-22 | 1986-07-02 | Gen Foods Ltd | Containers |
US4874237A (en) * | 1987-05-07 | 1989-10-17 | Lions Eye Inst. Of Western Australia | Electroretinogram apparatus |
EP0325201A3 (en) * | 1988-01-20 | 1990-01-31 | Etama Ag | Stimulating device to improve the sight of persons with a poor sight |
US4955378A (en) * | 1988-05-02 | 1990-09-11 | University Of South Florida | Apparatus and methods for performing electrofusion at specific anatomical sites |
CH684971A5 (en) * | 1989-03-16 | 1995-02-15 | Landis & Gyr Tech Innovat | Ultraviolet light sensor. |
US4989605A (en) * | 1989-03-31 | 1991-02-05 | Joel Rossen | Transcutaneous electrical nerve stimulation (TENS) device |
US5107835A (en) * | 1989-05-22 | 1992-04-28 | Physiodynamics | Electrotherapeutic treatment |
US5159927A (en) * | 1989-07-26 | 1992-11-03 | Ferdinand Schmid | Visual prosthesis apparatus and method |
US5016633A (en) * | 1989-08-08 | 1991-05-21 | Chow Alan Y | Artificial retina device |
US5024223A (en) * | 1989-08-08 | 1991-06-18 | Chow Alan Y | Artificial retina device |
RU1799577C (en) * | 1989-08-17 | 1993-03-07 | Межотраслевой научно-технический комплекс "Микрохирургия глаза" | Method for improving vision function affected by ophthalmic nerve and retina disease |
US5025811A (en) * | 1990-02-16 | 1991-06-25 | Dobrogowski Michael J | Method for focal destruction of eye tissue by electroablation |
GB2243082B (en) * | 1990-04-20 | 1994-02-16 | Marko Hawlina | Electrode for electroretinography |
US5099829A (en) * | 1990-04-25 | 1992-03-31 | Wu An Chuan | Massage device good for eyes |
US5109844A (en) * | 1990-10-11 | 1992-05-05 | Duke University | Retinal microstimulation |
US5130528A (en) * | 1991-03-01 | 1992-07-14 | International Business Machines Corporation | Opto-photo-electric switch |
JPH04365382A (en) * | 1991-06-13 | 1992-12-17 | Toshiba Corp | Semiconductor light-emitting device and its driving method |
JP2974469B2 (en) * | 1991-09-17 | 1999-11-10 | 株式会社東芝 | Signal transmission circuit |
US5223728A (en) * | 1992-04-02 | 1993-06-29 | Motorola, Inc. | Optical switch integrated circuit |
US5351309A (en) * | 1992-06-30 | 1994-09-27 | National Science Council | Image edge sensor |
US5760834A (en) * | 1992-09-30 | 1998-06-02 | Lsi Logic | Electronic camera with binary lens element array |
US5338991A (en) * | 1992-12-28 | 1994-08-16 | Lu Chao Cheng | High power solid state relay with input presence and polarity indication |
US5360438A (en) * | 1993-01-26 | 1994-11-01 | Fisher Mary R | Method and device for improving cranial nerve function to improve muscle function and thereby overcome visual/perceptual dysfunction |
US5397350A (en) * | 1993-05-03 | 1995-03-14 | Chow; Alan Y. | Independent photoelectric artificial retina device and method of using same |
US5556423A (en) * | 1993-05-03 | 1996-09-17 | Alan Y. Chow | Independent photoelectric artificial retina device and method of using same |
US5411540A (en) * | 1993-06-03 | 1995-05-02 | Massachusetts Institute Of Technology | Method and apparatus for preferential neuron stimulation |
US5578040A (en) * | 1994-06-14 | 1996-11-26 | Smith; Albert C. | Ocular repair system and apparatus |
US5522864A (en) * | 1994-10-25 | 1996-06-04 | Wallace; Larry B. | Apparatus and method for ocular treatment |
US5496355A (en) * | 1994-11-21 | 1996-03-05 | Lipsky; Stephen N. | Extraocular muscle sensor and stimulator |
EP0723984B1 (en) † | 1995-01-26 | 1999-12-08 | Saehan Industries, Inc. | Biodegradable copolyester and method for preparing the same |
JPH08297465A (en) * | 1995-04-26 | 1996-11-12 | Hiroshi Yamamoto | Optic nerve video output device and its method |
US5895415A (en) * | 1995-06-06 | 1999-04-20 | Optobionics Corporation | Multi-phasic microphotodiode retinal implant and adaptive imaging retinal stimulation system |
ES2218589T3 (en) * | 1995-06-06 | 2004-11-16 | Optobionics Corporation | RETINAL IMPLANT OF MULTIPHASIC MICROPHOTODYODE. |
DE19529371C3 (en) * | 1995-08-10 | 2003-05-28 | Nmi Univ Tuebingen | Microelectrode array |
US5717201A (en) * | 1996-04-18 | 1998-02-10 | National Science Council | Double four-quadrant angle-position detector |
US5895414A (en) * | 1996-04-19 | 1999-04-20 | Sanchez-Zambrano; Sergio | Pacemaker housing |
US6066675A (en) * | 1996-09-13 | 2000-05-23 | The Regents Of The University Of California | Method for treatment of retinal diseases |
WO1998017344A1 (en) * | 1996-10-23 | 1998-04-30 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Optically controllable microelectrode arrangement for stimulating cells, in particular a retina implant |
DE19705988C2 (en) * | 1996-10-23 | 2002-04-11 | Univ Eberhard Karls | Retinal implant |
US5837995A (en) * | 1996-11-25 | 1998-11-17 | Alan Y. Chow | Wavelength-controllable voltage-phase photodiode optoelectronic switch ("opsistor") |
US5865839A (en) * | 1996-12-30 | 1999-02-02 | Doorish; John F. | Artificial retina |
US5782894A (en) * | 1997-03-05 | 1998-07-21 | Israel; Ben | Device and method for improving ocular focusing at near vision points |
US6458157B1 (en) * | 1997-08-04 | 2002-10-01 | Suaning Gregg Joergen | Retinal stimulator |
US6083251A (en) * | 1997-11-13 | 2000-07-04 | Shindo; Kohei | Eye treatment method and apparatus |
FR2773320B1 (en) * | 1998-01-05 | 2000-03-03 | Optisinvest | DEVICE FOR INTRAOCULAR TRANSFER OF ACTIVE PRODUCTS BY IONTOPHORESIS |
US5944747A (en) * | 1998-03-13 | 1999-08-31 | Johns Hopkins University | Method for preferential outer retinal stimulation |
US5935155A (en) * | 1998-03-13 | 1999-08-10 | John Hopkins University, School Of Medicine | Visual prosthesis and method of using same |
US6324429B1 (en) * | 1998-05-08 | 2001-11-27 | Massachusetts Eye And Ear Infirmary | Chronically implantable retinal prosthesis |
US6035236A (en) * | 1998-07-13 | 2000-03-07 | Bionergy Therapeutics, Inc. | Methods and apparatus for electrical microcurrent stimulation therapy |
DE19838603A1 (en) * | 1998-08-25 | 2000-03-09 | Eldra Kunststofftechnik Gmbh | Decorative layer for airbag covers |
US6101411A (en) * | 1998-09-24 | 2000-08-08 | Newsome; David A. | Dilation enhancer |
US6282449B1 (en) * | 1998-10-21 | 2001-08-28 | William Kamerling | Method and device for causing the eye to focus on a near object |
WO2000056393A1 (en) * | 1999-03-24 | 2000-09-28 | Second Sight, Llc | Retinal color prosthesis for color sight restoration |
US6264971B1 (en) * | 1999-11-04 | 2001-07-24 | Btg International Limited | Ocular insert |
US6389317B1 (en) * | 2000-03-31 | 2002-05-14 | Optobionics Corporation | Multi-phasic microphotodetector retinal implant with variable voltage and current capability |
US6427087B1 (en) † | 2000-05-04 | 2002-07-30 | Optobionics Corporation | Artificial retina device with stimulating and ground return electrodes disposed on opposite sides of the neuroretina and method of attachment |
US6511508B1 (en) * | 2000-08-04 | 2003-01-28 | Environmental Robots, Inc. | Surgical correction of human eye refractive errors by active composite artificial muscle implants |
US6393327B1 (en) * | 2000-08-09 | 2002-05-21 | The United States Of America As Represented By The Secretary Of The Navy | Microelectronic stimulator array |
US6647297B2 (en) * | 2000-08-09 | 2003-11-11 | The United States Of America As Represented By The Secretary Of The Navy | Permanent retinal implant device |
US7103416B2 (en) * | 2001-01-16 | 2006-09-05 | Second Sight Medical Products, Inc. | Visual prosthesis including enhanced receiving and stimulating portion |
US20040106965A1 (en) † | 2001-06-29 | 2004-06-03 | Chow Alan Y. | Methods and apparatus for treatment of degenerative retinal disease via indirect electrical stimulation |
US7031776B2 (en) * | 2001-06-29 | 2006-04-18 | Optobionics | Methods for improving damaged retinal cell function |
US20050004625A1 (en) † | 2001-06-29 | 2005-01-06 | Chow Alan Y. | Treatment of degenerative retinal disease via electrical stimulation of surface structures |
US7003355B1 (en) * | 2001-11-20 | 2006-02-21 | Suaning Gregg J | Vision prosthesis for the blind and method for implementing same |
JP2003210513A (en) * | 2002-01-23 | 2003-07-29 | Nidek Co Ltd | Ophthalmic treatment equipment |
DE10304831A1 (en) | 2003-01-31 | 2004-08-26 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Retina implant to stimulate a retina depending on the light |
-
2004
- 2004-06-09 US US10/863,519 patent/US20050004625A1/en not_active Abandoned
- 2004-06-10 AU AU2004255156A patent/AU2004255156C1/en not_active Ceased
- 2004-06-10 CA CA2530171A patent/CA2530171C/en not_active Expired - Fee Related
- 2004-06-10 ES ES04755009T patent/ES2385809T5/en active Active
- 2004-06-10 EP EP04755009.0A patent/EP1635906B2/en active Active
- 2004-06-10 JP JP2006517228A patent/JP4654182B2/en not_active Expired - Fee Related
- 2004-06-10 WO PCT/US2004/018606 patent/WO2005004985A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP4654182B2 (en) | 2011-03-16 |
ES2385809T5 (en) | 2019-10-09 |
EP1635906B2 (en) | 2019-02-20 |
AU2004255156B2 (en) | 2010-09-16 |
EP1635906A2 (en) | 2006-03-22 |
WO2005004985A3 (en) | 2005-03-31 |
AU2004255156A1 (en) | 2005-01-20 |
US20050004625A1 (en) | 2005-01-06 |
AU2004255156C1 (en) | 2011-02-10 |
WO2005004985A2 (en) | 2005-01-20 |
JP2007521071A (en) | 2007-08-02 |
EP1635906B1 (en) | 2012-03-28 |
CA2530171A1 (en) | 2005-01-20 |
ES2385809T3 (en) | 2012-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2530171C (en) | Treatment of degenerative retinal disease via electrical stimulation of surface structures | |
US7031776B2 (en) | Methods for improving damaged retinal cell function | |
AU2002352103A1 (en) | Methods for improving damaged retinal cell function | |
US20040106965A1 (en) | Methods and apparatus for treatment of degenerative retinal disease via indirect electrical stimulation | |
US7877148B2 (en) | Extraocular device | |
O’Hearn et al. | Electrical stimulation in normal and retinal degeneration (rd1) isolated mouse retina | |
WO2021238415A1 (en) | Implant apparatus, and visual prosthesis having same | |
Sun et al. | Spatiotemporal properties of multipeaked electrically evoked potentials elicited by penetrative optic nerve stimulation in rabbits | |
US20060224212A1 (en) | Neural electrode array | |
Matthaei et al. | Progress in the development of vision prostheses | |
Hetling et al. | Neural prostheses for vision: designing a functional interface with retinal neurons | |
Chow | Retinal prostheses development in retinitis pigmentosa patients—progress and comparison | |
Sui et al. | Evaluation of a MEMS-based dual metal-layer thin-film microelectrode array for suprachoroidal electrical stimulation | |
Liang et al. | Threshold suprachoroidal-transretinal stimulation current required by different-size electrodes in rabbit eyes | |
WO2021238419A1 (en) | Implantation device and visual prosthesis having same | |
AU2004226908B2 (en) | Extraocular device | |
Suaning | Strategic circuits for neuromodulation of the visual system | |
Chow et al. | The semiconductor-based microphotodiode array artificial silicon retina | |
Fujikado et al. | Artificial vision: vision of a newcomer | |
Gerding | The Minimally invasive retina implant project | |
Walter et al. | Experimental implantation of devices for electrical retinal stimulation in rabbits: preliminary results | |
Siu | Artificial vision: feasibility of an episcleral retinal prosthesis & implications of neuroplasticity | |
AU2002312620A1 (en) | Methods for improving damaged retinal cell function using physical and/or mechanical stimulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20180611 |